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This thesis is presented as an icon of all the hard work started in the year 2012 until the 
year 2015.  This thesis was undertaken as part of the requirements for the Doctor of 
Clinical Dentistry (DClinDent) Special Needs Dentistry degree from the University of 
Otago, New Zealand.  Nine antipsychotic medications users were recruited as 
participants in this study, who answered 11-item Xerostomia Inventory (XI), had oral 
examinations, mucosal smears and saliva collection.  The saliva was further tested for 
the presence of Candida hyphae, Candida species identification and quantification and 
antifungal susceptibility of Candida albicans.   
 
This thesis contains five chapters including the literature review, materials and methods, 
results chapter (study participants and microbiological analysis) and discussion.  The 
‘study participants’ chapter contains results from the clinical aspect including details on 
participant’s sociodemographic characteristics, medical history and medications; and 
the cytological analysis of the thesis.  The microbiological analysis contains detailed 
findings obtained from the microbiological aspect of the thesis including the 
identification and quantification of the Candida species obtained from participants, the 
susceptibility of C. albicans against fluconazole and fluphenazine based on two 
methods; the Etest™ and the liquid microtitre assay.  The antagonism/synergism of the 
combination of fluconazole and fluphenazine was also tested using two methods; the 
disc diffusion assay and the liquid microtitre assay.  The discussion chapter elaborates 
the analysis of the findings, conclusions, limitations of the study and future research 







Objective: The overall objective of this project was to investigate oral 
Candida carriage and antifungal susceptibility of Candida albicans isolates in patients 
receiving antipsychotic medications.  Specific objectives were: to determine the level 
of colonisation with Candida of the oral mucosa in individuals taking antipsychotic 
medications relative to healthy controls and to xerostomic individuals not prescribed 
with antipsychotics; to determine the Candida species present; to measure the azole 
resistance of these isolates; and to determine whether the antipsychotic medication 
fluphenazine affected azole resistance of C. albicans isolates. 
 
Methods: Nine participants aged between 20 and 70, who were currently on 
antipsychotic medications were recruited into this study with informed consent.  
Xerostomia symptoms were determined from the Xerostomia Inventory (XI) and 
clinical examinations.  Saliva rinses were collected by asking each participant to rinse 
their mouth with 10 mL water for 30 s and then expectorated into specimen bottles.  
Smears were taken from the buccal mucosa (both sides), tongue, and any other 
mucosal site with signs of infection.  Smears were sent to Medlab for Candida hyphae 
and yeast identification.  Saliva samples were diluted and cultured on CHROMagar 
Candida™ plates.  The colony-forming units (CFU) and species (presumptively 
assigned from the colony colour) were recorded.  The susceptibility of the C. albicans 
isolates to fluconazole was measured using the E-test and liquid microdilution assay.  
The interaction between fluconazole and fluphenazine was investigated using a                               
disc diffusion assay and checkerboard liquid microdilution assay.        
 
Results:  The majority of the participants (78%) presented with dry mouth.  However, 
the degree of dry mouth symptoms they experienced was not severe based on their XI 
scores.  Four of nine participants (44%) were diagnosed with oral candidosis.  The 
infection coincided with antipsychotic medication intake, although may not have been 
caused by the antipsychotic because three of the four participants were on other 
medications as well.  Higher numbers of participants were colonised with Candida 
spp. (7 of 9) compared to an age-matched group of healthy individuals (2 of 9).  The 
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numbers of yeast detected per participant was also significantly higher than for the 
control group.  The Candida species most frequently presumptively identified by 
colony colour on CHROMagar Candida™ was C. albicans.   Fluphenazine showed 
low antifungal activity.  However, fluphenazine was found to produce antagonistic 
effects towards fluconazole, both in disc diffusion assays and the more quantitative 
checkerboard MIC assays.  
 
Conclusion: Many antipsychotic medications are known to cause xerostomia and 
predispose to Candida infections. Investigating C. albicans infections and their 
resistance to fluconazole will potentially lead to more appropriate treatment.  The 
discovery that antagonism between the antipsychotic fluphenazine and fluconazole 
occurs with C. albicans clinical isolates indicates that careful consideration is 
necessary when prescribing fluconazole to patients currently taking fluphenazine or 
medications of a similar class.  Other antifungal agents such as nystatin lozenges (not 
readily available in New Zealand) and amphotericin B lozenges might be better for 
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The New Zealand Mental Health Survey, 2012/13, concluded that one in six adults 
(16%) of the New Zealand population experienced mental disorders at some time in 
their life.  Some will have been prescribed with antipsychotic medications.  The use 
of antipsychotic medications has helped reduce the number of hospitalisations due to 
psychiatric disorders and more patients are integrated into the society.  However, 
these medications have several adverse effects, including reducing salivary gland 
function.  The World Health Organisation (WHO) defined the term adverse effect as 
“a response to a drug that is noxious and unintended and occurs at doses normally 
used in man for the prophylaxis, diagnosis or therapy of disease, or for modification 
of physiological function” (WHO, 1972 as cited in Edwards and Aronson, 2000).  All 
unwanted effects from medications could be termed as adverse effects.   
 
One of the consequences of reduced salivary flow is a dry mouth.  Xerostomia is a 
subjective feeling of dry mouth, almost always accompanied by reduced unstimulated 
(resting) salivary flow (Sreebny and Schwartz, 1987).  Causes of dry mouth could be 
classified as irreversible or permanent and transient or reversible.  Examples of 
irreversible damage are irradiation to the salivary gland and autoimmune diseases 
such as sicca syndrome or Sjogren’s syndrome.  Dry mouth due to the effects of 
medications is usually transient or reversible.  The diagnosis of dry mouth is based on 
the patient’s history, clinical oral examination and sialometry (a simple procedure for 
measuring salivary flow).  It is accepted that people with xerostomia of any aetiology 
are at higher risk of developing oral fungal infections, especially those caused by 
Candida species (Torres et al. 2003).  While there have been many reports of the 
association between dry mouth and use of antidepressant medications, there is little 
known about the effects of antipsychotic medication on salivary flow.  In addition, the 
antipsychotic fluphenazine is known to induce expression of efflux pumps in Candida 
albicans that cause resistance to the antifungal azole medications (de Micheli et al., 
2002, Coste et al., 2004, Manoharlal et al., 2011).  Therefore, not only may patients 
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taking antipsychotics be more susceptible to candidosis, their infections may not 




Clinicians often use the Diagnostic and Statistical Manual of Mental Disorders-fourth 
edition (DSM-IV) (American Psychiatric Association, 1994) for the diagnosis and 
classifications of psychiatric disorders.  Another method commonly used for 
diagnosis and classification of mental health problems is the International Statistical 
Classification of Diseases and Related Health Problems of the WHO, version 10 
(ICD-10).  The common mental health problems include anxiety, depression, phobias, 
obsessive compulsive and panic disorders.  A less common psychiatric disorder is 
psychosis that manifests with symptoms that interfere with the person’s perception of 
reality with loss of insights.  It includes hallucinations and other mental health 
problems such as schizophrenia and bipolar affective disorder (manic depression). 
Mental disorders are difficult to categorise due to the difficulty in diagnosis, thus they 
may result in inconsistent treatment outcomes (Hyman, 2010).  
 
Antipsychotic medications (also known as psychotropic or psychotherapeutic or 
neuroleptic medications) were first introduced in the 1950s.  They were mainly used 
as treatment and maintenance therapy for people with severe and persistent mental 
illnesses.  These conditions include dementia, delirium (acute state of confusion), 
psychosis, agitation and affective disorders (Wang et al., 2005).  The principal action 
of antipsychotics is on the dopamine system (Miyamoto et al., 2005).  
Pharmacologically, there are two classes of antipsychotic medications: first-
generation (typical) and the newer, second-generation (atypical) antipsychotics.  
Figure 1.1 illustrates the classification of antipsychotic medications based on their 
chemical structures and provides examples of typical and atypical antipsychotic 
medications.  Highlighted in orange colour are the typical antipsychotic medications 
and highlighted in green are the atypical antipsychotic medications.   





Figure 1.1 Groups of antipsychotic medications with examples.  Boxes highlighted in orange colour are the typical antipsychotics, green boxes 





















The pharmacological action of typical (conventional) antipsychotic medications, also 
known as first-generation antipsychotic medications or neuroleptics, is primarily by 
blocking the dopamine D2 receptors in the dopamine pathways.  These medications 
are effective in controlling active symptoms of psychosis, reducing assaultive 
behaviour, managing severe agitation and reducing the risk of relapse in psychotic 
disorders during maintenance period (Jibson and Tandon, 1998).  Typical 
antipsychotic medications are grouped into phenothiazines including chlorpromazine, 
levomepromazine (methotrimeprazine), perphenazine, prochlorperazine, promazine, 
fluphenazine and trifluoperazine; and the butyrophenones group such as haloperidol.  
Medications that belong in the phenothiazine group are chlorpromazine, fluphenazine, 
mesoridazine, perphenazine, prochlorperazine, thiethylperazine, thioridazine, triavil 
(perphenazine/amitriptyline) and trifluoperazine.  Haloperidol belongs to the 
butyrophenone group, loxapine belongs to the dibenzoxapine group, molindone 
belongs to the dihydroindolone group and thioxetene in the thioxantene group.  
Fluphenazine decanoate (brand name Modecate) belongs to the piperazine class of 
phenothiazines and haloperidol decanoate (brand name Haldol) are typical 
antipsychotic medications commonly used as depot medication (long-acting), which 
are administered by injection every two to four weeks.  Fluphenazine enanthate 
(Moditen) is also given orally.  They are often prescribed when patients are non-
compliant with oral medications especially in schizophrenia (Valenstein et al., 2001).   
 
Typical antipsychotic medications can also be divided into groups based on their 
sedative effects.  There are three main groups. Chlorpromazine (50-1000 mg daily), 
for example belongs to a group characterised by profound sedative and moderate 
antimuscarinic and extrapyramidal effects.  The other two groups are characterised by 
moderate sedative effects with marked antimuscarinic effects and fewer 
extrapyramidal effects, such as thioridazine (25-250 mg daily), and a group 
characterised by fewer sedative and antimuscarinic effects but more pronounced 
extrapyramidal effects, for example trifluoperazine (2030 mg daily), haloperidol (2-80 
mg daily) and flupentixol (2-100 mg daily).  
 




The atypical antipsychotic medications are classified as phenothiazines, 
butyrophenone, dibenzoxapine, dihydroindolone and thioxantene (Williams et al., 
1999).  Atypical antipsychotic medications provide therapeutic effects, more effective 
for the treatment of negative symptoms of schizophrenia and tend to produce less 
extrapyramidal side effects.  Pharmacologically, they are also antagonists of 
dopamine D2 receptors with additional antagonistic effects on muscarinic, cholinergic, 
histaminergic, noradrenergic and serotonic receptors.  These medications produce less 
extrapyramidal side effects due to antagonistic actions on 5-hydroxytriptamine 
(serotonin) receptor 2A (5HT2A) receptors, making them different from the typical 
antipsychotic medications.  Examples of atypical antipsychotic medications are 
aripiprazole, clozapine, olanzapine, quetiapine, tiapride, risperidone and pipamperone 
dihydrochloride.  Clozapine was approved for use in the United States in 1989 for 
treatment of positive and negative symptoms of schizophrenia.  Positive symptoms 
(florid) in schizophrenia are psychotic behaviours not seen in healthy individuals 
delusions and hallucinations, while negative symptoms (defect) are symptoms 
associated with disruptions in normal behaviour and emotions such as attentional 
impairment (Andreasen and Olsen, 1982).  It is effective in treating schizophrenia 
with a relatively low frequency of extrapyramidal and endocrine side effects due to its 
selectiveness in blocking mesolimbic and mesocortical dopaminergic pathways 
(Jibson and Tandon, 1998).  
 
Prescription of typical antipsychotic medications is reducing and being replaced by 
the use of atypical antipsychotic medications resulting in fewer extrapyramidal side 
effects and lower risk of tardive dyskinesia (Meltzer, 2004).  In Australia in 2001, 
67.3% of prescribed antipsychotic medications were atypical versus 16.0% typical 
antipsychotics, whilst 16.7% were depot medications (Mond et al., 2003).   





There are several adverse effects associated with antipsychotic medications.  These 
include extrapyramidal side effects, anti-cholinergic effects including dry mouth, anti-
adrenergic effects, electrocardiography (ECG) and electroencephalography (EEG) 
alterations, neuroleptic malignant syndrome, dermatological effects, haematological 
effects, ophthalmological effects, weight gain and seizures (Whitworth and 
Fleischhacker, 1995).  They also induce hyperglycaemia and dyslipidaemia as 
additional side effects (Miyamoto et al., 2005).  Adverse effects are dependent on 
dosage, patient characteristics, age and gender (Haddad and Sharma, 2007).  The side 
effects of antipsychotic medications can appear as acute or chronic, and may be very 
detrimental to patients although the difficulties with side effects have to be weighed 
up against management of the primary pathology.  The side effects vary according to 





Conventional (typical) antipsychotic medications produce various adverse reactions.  
These reactions have been divided into physiologic changes, sexual and reproductive 
side effects and central nervous system (CNS) side effects.  Physiologic changes are 
associated with changes in the autonomic and cardiovascular system; endocrinologic 
and metabolic; haematologic and hepatic; allergic, dermatologic and ophthalmologic.  
Potentially lethal adverse effects are the cardiac changes such as tachycardia and ECG 
changes that may lead to cardiac arrhythmia.  Other effects include postural 
hypotension, seizures and dry mouth (Arana, 2000).  Zelickson and Rogers (1986) 
concluded that conventional (typical) antipsychotic medications such as 
chlorpromazine, thioridazine, haloperidol and prochlorperazine cause xerostomia in 
patients.  Endocrinologic effects of the typical antipsychotics include gynaecomastia, 
amenorrhea in women and impotence in men associated with hyperprolactinaemia.  
Typical antipsychotics may cause hyperprolactinaemia via the blockade of dopamine 
receptors in the pituitary prolactin-secreting cells.  Other metabolic effects are weight  
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gain, hyperpyrexia and hypopyrexia (Arana, 2000).  In the haematological system, 
leukocytosis as well as leukopaenia can be also associated with typical antipyschotics; 
these changes occur within three to six weeks after commencement of treatment.  
Photosensitivity and other skin reactions associated with allergy may occur with the 
use of typical antipsychotics.  Skin hyperpigmentation was also reported in patients 
with high-dose long-term chlorpromazine.  Ophthalmologic side effects associated 
with typical antipsychotics may lead to blindness.  They also may have teratogenicity 
effects when taken by pregnant mothers and may cause neurological defects to 
breastfed babies (Arana, 2000). 
 
Movement disorders associated with typical antipsychotic medications, particularly 
phenothiazines and butyrophenones are the extrapyramidal disorders consisting of 
tremor, akathisia, dystonia, bradykinesia and dyskinesia.  Patients may develop acute 
dystonia, neuroleptic drug-induced Parkinsonism, bradykinesia, akathisia, rabbit 
syndrome and tardive dyskinesia (Casey, 1991).  A tremor caused by antipsychotic 
medications occurs with a certain duration of exposure to the antipsychotic drug 
characterised by rhythmic, involuntary muscle contractions particularly intention 
tremor and resting tremor (Collins et al., 1979).  Intention tremor is defined by 
increased amplitude during a visually guided movement towards a target at the 
termination of movement, while resting tremor occurs when a body is at complete rest 
against gravity for example while seating (Deuschl et al., 1998).  Akathisia is 
sometimes described as anxiety with restlessness and resembles psychotic agitation 
(Arana, 2000).  Akathisia literally means “unable to sit” (derived from a Greek word).  
Neuroleptic-induced akathisia is a side effect of antipsychotic medications 
characterised by a sense of restlessness especially in the legs, inability to remain 
seated and shuffling from foot to foot or pacing (Adler et al., 1989).  Dystonia is 
characterised by sustained or intermittent muscle contractions causing abnormal 
movements (usually repetitive), postures or both (Albanese et al., 2013).  It is 
characterised by involuntary muscle spasm that results in abnormal postures 
including, oculogyric crisis, tongue protrusion, trismus, torticollis, laryngeal-
pharyngeal constriction, or bizarre positions of the limbs and trunk.  Patients may 
have a reduction in spontaneous activity (Arana, 2000) or slowness in executing 
movements (Sheridan and Flowers, 1990) known as bradykinesia.  Akinesia is a 
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condition that mimics the negative symptoms of schizophrenia or the psychomotor 
retardation of depression (Arana, 2000).  Tardive dyskinesia is a debilitating 
neurologic disorder characterised by repetitive, involuntary and purposeless 
movements that usually involves the tongue, jaw, lips, face, trunk, limbs and 
respiratory system (Margolese et al., 2005).   Rabbit syndrome is characterised by 
rhythmical tremors in the lips and perioral area, and usually responds to anti-
extrapyramidal syndrome medications (Casey, 1991).  It causes rapid and regular 
orofacial movement disorder with tongue sparing (Deshmukh et al., 1990).   
 
The adverse effects of antipsychotic medications may appear as acute or chronic 
depending on the duration of exposure to the medications.  Akathisia is an early, 
usually intolerable side effect of typical antipsychotic drug.  Acute dystonia often 
occurs during the first week of therapy, usually within four days or shortly after a 
dose increase involving involuntary muscle spasms.  Sometimes it can be 
misdiagnosed as hysteria or malingering (Arana, 2000).  Prolonged contraction of the 
muscles due to dystonia may become detrimental or life-threatening especially the 
laryngeal spasms (Arana, 2000).  Tardive dyskinesia is an adverse effect associated 
with long-term use of typical antipsychotic medications.  It is often irreversible 
causing disfigurement to the patients and may interfere with normal daily activities 
(Arana, 2000; Margolese et al., 2005).  Bradykinesia is an adverse effect often 
misdiagnosed by failure to recognise this condition and the patient is thought to have 
depression, psychological withdrawal or negative symptoms of schizophrenia (Arana, 
2000).  A rare but potentially fatal side effect of antipsychotic medications is 
neuroleptic malignant syndrome (NMS), characterised by hyperthermia, confusion, 
muscular rigidity and autonomic disturbances such as tachycardia, labile blood 
pressure and sweating.  Other movement disorder includes neuroleptic drug-induced 
Parkinsonism that manifests similarly to idiopathic Parkinsonism.  Careful 
prescriptions of typical antipsychotics are necessary to reduce the risk of seizures 
especially in high-risk patients, such as patients with history of seizures.  A rare 
condition that may appear following antipsychotic medications is rabbit syndrome 
that manifests as a mild Parkinsonism especially around the lip and perioral region 
(Casey, 1991).  Almost all the adverse effects of typical antipsychotic medications not 
only affect the level of compliance in patients but also the quality of life of the 
patients (Arana, 2000).   





The risk of developing extrapyramidal side effects (Parkinsonism, akathisia and acute 
dystonia) due to atypical antipsychotics including amisulpiride, clozapine, olanzapine, 
quetiapine and risperidone was lower when compared to haloperidol (Haddad and 
Sharma, 2007).  Similarly, the risk of tardive dyskinesia was lower with atypical 
antipsychotic medications, especially clozapine and quetiapine, when compared to 
haloperidol.  In regards to antipsychotic drug-induced hyperprolactinaemia, 
risperidone and amisulpiride may cause an increase in prolactin hormone; clozapine 
and quetiapine do not increase the prolactin level; olanzapine and ziprasidone may 
cause increased prolactin level at higher dose (Haddad and Sharma, 2007).  However, 
all atypical antipsychotic medications cause significant weight gains (>7%) especially 
clozapine and olanzapine (Haddad and Sharma, 2007).  The anticholinergic side 
effects including dry mouth, blurred vision, urinary retention, constipation and 
cognitive impairment due to atypical antipsychotic medications were dose-dependent.  
Olanzapine was found to cause dry mouth as a side effect (Tollefson et al., 2001).  
Dry mouth is also reported in users of quetiapine (Bagnall et al., 2003; Srisurapanont 
et al., 2004), risperidone (Mullen et al., 2001), tiapride and pipamperone 
dihydrochloride (Scully, 2003).  The incidence of dry mouth is higher when 
olanzapine is combined with lithium when compared to olanzapine therapy alone 
(Tohen et al., 2002). 
 
Clozapine was introduced in the U.S.A in early 1970s but was withdrawn from the 
market due the risk of agranulocytosis.  However, it was approved and released back 
into the market in January 1990 by the U.S Food and Drug Administration (FDA) 
with careful dispensing and monitoring procedures.  Clozapine is the only 
antipsychotic drug shown in clinical trials to effectively reduce positive and negative 
symptoms in schizophrenia patients non-responsive to typical antipsychotic 
medications.  The risk of agranulocytosis from clozapine use is about 1% to 2% in the 
first six months, whilst the risk of seizures is dose-dependent within a range of 2% to 
6%.  Agranulocytosis (granulocyte count <500/mm3) is a life-threatening condition, 
with the mortality rate of 3% to 4% (Iqbal et al., 2003).  Iqbal and colleagues listed 
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the various adverse effects of clozapine in their article.  Clozapine produces multiple 
adverse effects associated with the haematologic system, CNS, neuromuscular 
system, cardiovascular system, autonomic nervous system and gastrointestinal 
system.  It also produces metabolic effects for example weight gain and diabetes 
mellitus and may be associated with urinary incontinence.  The incidence of seizures 
increases with clozapine use, and is dose-dependent.  Hypersalivation, drooling and 
choking sensation due to excessive saliva are common complaints by patients taking 
clozapine.  They are dose-dependent and adjunctive treatment may be needed to 
reduce hypersalivation (Iqbal et al., 2003).  It was unclear whether it truly causes 
hypersalivation via activation of muscarinic M4 receptors or blockade of α2-
adrenoceptors or by causing impairment in the swallowing mechanisms causing saliva 
pooling in the mouth (Davydov and Botts, 2000; Haddad and Sharma, 2007). 
However, animal studies show that it induces saliva secretion via direct action on the 
muscarinic receptor (M1) of the acinar cells (Ekström et al., 2010).  
 






















Chlorpromazine Xerostomia, hyperprolactinaemia, 
weight gain, hyper/hypopyrexia, 
leukocytosis, leukopaenia, skin 
reaction, blindness, teratogenic, 
























Amisulpiride Hyperprolactinaemia, weight gain, 
dry mouth, blurred vision, urinary 
retention, constipation 
 
Clozapine Movement disorders, weight gain, 
hypersalivation, agranulocytosis, 
diabetes mellitus, blurred vision, 
urinary retention, constipation, 
seizures 
 
Olanzapine Hyperprolactinaemia (higher dose), 
weight gain, dry mouth, blurred 
vision, urinary retention, constipation 
 
Quetiapine Movement disorders, weight gain, 
dry mouth, blurred vision, urinary 
retention, constipation 
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 Antipsychotic medications 
 
Side-effects 
Risperidone Hyperprolactinaemia, weight gain, 
dry mouth, blurred vision, urinary 
retention, constipation 
 
Ziprasidone Hyperprolactinaemia (higher dose), 
weight gain, dry mouth, blurred 
vision, urinary retention, constipation 
 






The terminology xerostomia, dry mouth, salivary gland hypofunction and 
hyposalivation often cause confusion between clinicians and researchers.  Most 
authors agree that xerostomia is not a diagnosis but a symptom.  In a review by 
Nederfors (2000), xerostomia was recognised as the subjective feeling of oral dryness, 
while hyposalivation was a sign of decreased salivary flow rate.  Salivary gland 
hypofunction was a condition with subjective feeling of dry mouth combined with 
signs of decreased salivary flow rate.  However, there is no global consensus on the 
term ‘dry mouth’.  In this particular study, xerostomia, the subjective feeling of oral 




There are multiple possible causes of xerostomia including salivary and non-salivary 
causes.  Salivary causes of xerostomia include hyposalivation and/or alteration in 
salivary composition.  Examples of salivary causes of xerostomia due to salivary 
gland hypofunction or hyposalivation are salivary gland trauma or tumour, nutritional 
deficiencies and/or eating disorders (anorexia, bulimia), systemic diseases such as 
Sjogren’s syndrome or from side effects of medications and radiation therapy to the 
head and neck (Napeñas et al., 2009).   Non-salivary causes of complaints of 
xerostomia are oral sensory dysfunction, neurological dysfunction, central cognitive 
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changes, psychological causes, mouth breathing and dehydration.  Medical 
interventions such as radiotherapy in the head and neck region, prescription of oral 
radionuclides such as iodine 131 (I131) for thyroid disease treatment and bone marrow 
transplantation with graft-versus-host disease may cause xerostomia (Fox, 2008; 
Guggenheimer and Moore, 2003).  Systemic diseases that may cause xerostomia 
include diabetes mellitus, depression, anxiety and Sjogren’s syndrome.  Other 
possible causes for xerostomia are tobacco smoking, alcohol use (including 
mouthwashes) and caffeine (coffee, tea and soft drinks) consumption (Scully, 2003).  
The mechanism of action for drug-related xerostomia is anticholinergic activity.   
 
There are a great number of medications that have xerostomia as one of their side 
effects.  Medications that are known to cause xerostomia include anticholinergic 
agents, antidepressant and antipsychotic agents, diuretics, antihypertensive agents, 
sedatives and anxiolytics, muscle relaxants, analgesics (opioids and non-steroidal 
anti-inflammatory medications (NSAIDs)), antihistamines, anti-acne medications, 
anti-convulsants, anti-dysrythmics, anti-incontinence agents, anti-Parkinsonian 
agents, bronchodilators, ophthalmic formulations and smoking cessation agents 
(Guggenheimer and Moore, 2003).   In a review by Scully (2003), the most common 
oral adverse drug reaction in the USA was found to be dry mouth (80.5%) and the use 
of psychiatric medications was the main cause for dry mouth (Pajukoski et al., 2001).  
Subjective oral dryness was also associated with age, female gender, and intake of 
antipsychotic medications, anti-asthmatics and diuretics (Bergdahl and Bergdahl, 




People suffering from reduced salivary flow (hyposalivation) may present with oral 
complaints such as dry mouth, burning mouth or altered taste sensation.  They may 
complain of difficulty in eating, speaking and swallowing certain foods or they may 
find the increased need to drink water.  Halitosis and intolerance to spicy food may 
also be found (Cho et al., 2010).  Clinical manifestations of xerostomia are tongue 
changes such as atrophy of the filiform papillae, fissured tongue, and erythematous 
mucosa with a parched appearance (Guggenheimer and Moore, 2003).  Other 
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manifestations of xerostomia are dried and cracked lips, glossy or desiccated oral 
mucosa, frothy saliva and lack of saliva pooling in the floor of the mouth (Napeñas et 




Longman et al. (2000) studied the diagnosis of salivary hypofunction based on three 
aspects; patient reported subjective feeling of xerostomia, clinical presentation and 
sialometry (of unstimulated whole saliva).  They underlined three categories for oral 
dryness; moist mouth, ‘parchment appearance’ and dry mouth with small amount of 
frothy saliva.  The ‘parchment appearance’ was defined as when there was no saliva 
coating on the dorsum of the tongue, on the buccal mucosa and no saliva pooling at 
the floor of the mouth.  They found that these diagnostic criteria could predict salivary 




A number of tests can be undertaken to measure the subjective feeling of xerostomia.  
The use of a visual analogue ruler, single-item questionnaire and multiple-item 
questionnaire were developed in order to help clinicians and researchers to identify 
and classify xerostomia.  Some of the questions were limited to a ‘yes’ or ‘no’ 
answer.   
 
Thomson et al. (1999) developed a multi-dimensional questionnaire approach, the 
Xerostomia Inventory (XI) to classify the severity of xerostomia based on 
respondents’ experience of, and behaviour towards, dry mouth.  The XI was based on 
a continuous scale for the measurement of xerostomia unlike the other previous 
measurement methods.  They compared the multiple approaches that were available 
during that time.  They found that the single-item approach was limited to only 
measuring dry mouth without exploring the other symptoms associated with the 
experience of xerostomia.  The XI uses the question “how often does your mouth feel 
dry?” followed by 11-item questions with the answering options of “never”, “hardly 
ever”, “occasionally”, “fairly often” and “very often”.  Each item was given a score 
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between 1 and 5 and the scores were then summated.  The score of 1 was given to the 
answer “never”, score 2 for “hardly ever”, score 3 for “occasionally”, score 4 for 
“fairly often” and score 5 for “very often”.  The sum of scores ranges from 11 to 55.  
This approach has subsequently been validated (Thomson et al., 2000; Thomson, 
2007; Hopcraft et al., 2010).  The mean XI scores based on individual answers of 
“never”, “occasionally”, “often” and “always” provide the investigator with 
information about the level of severity of the patients’ xerostomia symptoms.  
 
The original XI was produced in 1999 with the purpose of measuring xerostomia in a 
continuous scale method to reduce the misclassification of xerostomia based on an 
arbitrary cut-off point (Thomson et al., 1999).  The XI was shortened in 2011, when a 
Dutch version of the shortened XI was used (Thomson et al., 2011).  Instead of using 
the 11-item questionnaire, they used 5-item questionnaire with three answering 
options.  The items that were used were “my mouth feels dry when eating a meal; my 
mouth feels dry; I have difficulty in eating dry foods; I have difficulty in swallowing 
certain foods and my lips feel dry”.  The answering options provided were “never” 
giving the score of 1, “occasionally” scores 2 and “often” scores 3.  However, the 
shortened version of XI was limited to studying participants’ level of dry mouth.  The 
purpose of the shortened XI was to develop a day-to-day clinical measure; and for 
researchers to retain the most important properties and characteristics of xerostomia.  
Respondents were found to be confused with the five answering options given, thus 
the shortened version provided only three.  This measure was proven valid with the 
original version of XI, although the sample number used was not representative of 
population.  Thomson and colleagues (2011) proposed that researchers should use the 
XI with the standard question “How often does your mouth feel dry?” followed by 4 
answering options (“Never”, “Occasionally”, “Frequently” and “Always”) to provide 
a validity check.  Thus this form of the XI was used in the present study with four 
answering options provided to the respondents (“Never”, “Occasionally”, 
“Frequently” and “Always”).  The scoring system was 1 for “Never”, 2 for 
“Occasionally”, 3 for “Frequently” and 4 for “Always” giving a range of total score 
between 11 and 44.        
   
Interviews can be also be used to gain information about xerostomia and the use of a 
visual analogue scale (VAS) or a categorical scale can provide quantitative data (Cho 
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et al., 2010).  One example of a visual analogue scale is the Likert scale (Figure 1.2).  
The Likert scale is a psychometric scale developed by Rensis Likert (Esterman, 2003) 
which uses a 5-point scale of 1, 2, 3, 4 and 5. (1=mouth feels moist to 5=mouth 
extremely dry, tongue sticks to palate, difficulties with speaking). 
 
 
Please rate how dry your mouth feels (Circle one most appropriate answer) 
 
  1                            2                            3                               4                            5 
mouth                                                                                                   mouth extremely 
feels                                                                                                     dry, tongue sticks 
moist                                                                                                    to palate, with 
                                                                                                     speaking difficulty 
 




Measuring the salivary output can determine salivary flow.  Collection of 
unstimulated whole saliva at a rate of 0.12 to 0.16 ml per minute, or stimulated whole 
saliva at a rate of less than 0.5 ml per minute may indicate salivary hypofunction 
(Napeñas et al., 2009; Navazesh et al. 1992).  Navazesh and Kumar (2008) outlined 
the methods for measuring salivary output.  Output that can be measured includes 
whole unstimulated saliva, whole stimulated saliva or saliva from individual salivary 
glands.  Several stimulants have been used in various studies including gum base, 
paraffin wax, rubber bands, citric acid, secretagogues such as cevimeline 
hydrochloride and pilocarpine and also mechanical stimulants such as transcutaneous 
electrical nerve stimulator and powered toothbrushes.  Collection of whole saliva 
from the mouth can be performed by spitting, draining or by weighing cotton rolls 
inserted into the mouth.  Stimulated salivary output collection is performed by using 
stimulants, such as applying 2% citric acid to the dorsum surface of the tongue or by 
mechanical stimulation for example by chewing.  The collection of saliva from 
parotid glands is performed by using a catheter inserted into the parotid duct to drain 
the saliva or by using a suction cup.  Saliva collection from submandibular or 
sublingual glands can be performed by selective suctioning technique from the 
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glands’ orifice at the floor of the mouth.  Patients with Sjogren’s syndrome may need 
to undergo minor salivary gland output measurement from the lip.  Although there is 
no standardised method for measuring salivary output, whole saliva measurement is 
considered acceptable for investigating the general level of xerostomia in patients or 
the relationship between symptoms and salivary output (Eisbruch et al., 2003). 
Collection of unstimulated whole saliva is easy, but it is sensitive to the hydration 
status of the patients and medications that may induce xerostomia.  This is one of the 
reasons why the method of unstimulated whole saliva collection was chosen for this 
study.   
 
The collection of whole unstimulated saliva is performed by advising the individuals 
to rinse their mouth with distilled water, minimise movement in their mouth, head 
tilting slightly forward, then collect remaining saliva in their mouth and expectorate 
into the collection tube after 1 minute.  They should refrain from eating or drinking 
for one hour before the procedure.  It is advisable to ask them to practice a few times 
before the actual collection.  Stimulated whole saliva collection using chewing gum 
(or other agent) usually takes five minutes and is performed by asking the patient to 
swallow his or her saliva, followed by chewing the gum base (no flavours) and then 
spitting into a tube once every minute, without swallowing.  For the first two minutes 
saliva is collected into a cup; for the remaining three minutes the saliva is collected in 
a tube. Collecting saliva from the parotid gland is performed via Stensen’s duct 
situated opposite the maxillary second molar using a special collecting cup.  Saliva 
from submandibular and sublingual glands is collected via Wharton’s duct situated in 
the floor of the mouth.  Hyposalivation is defined as an unstimulated salivary flow of 
less than 0.1ml per minute (Bergdahl and Bergdahl, 2000) or whole stimulated saliva 




Clinical identification of dry mouth can be performed by oral examination, including 
examination of the salivary glands and the associated ducts.  The salivary glands 
should be examined for enlargement or asymmetry, tenderness on palpation, lack of 
saliva on palpation, atrophic Stensen or Wharton duct and contaminated saliva (with 
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pus or blood).  Lack of saliva pooling may indicate dry mouth, as may a dry, 
desiccated, atrophic, fissured, lobulated or discoloured mucosa.  Examination of the 
teeth and gums may show evidence of carious lesions and/or gingivitis (Navazesh, 
2003).  Navazesh et al. (1992) identified the combination of four clinical measures 
that successfully predicted the presence of dry mouth, namely; dry lips, dry buccal 
mucosa, absence of saliva from salivary gland palpation and total DMFT (Decayed- 
Missing-Filled Teeth).  However, they proposed that at least another diagnostic 
procedure should be done along with the clinical evaluations to confirm the diagnosis.  
They tested the salivary output against the other signs of dry mouth including lack of 
salivary pooling in the mouth, tongue mucosal changes, increased Candida count and 
higher gingival index.  Although these signs were found more in participants with low 




Radiographic imaging such as scintigraphy or sialography may also help in 
determining salivary gland function or dysfunction.  Scintigraphy is a minimally 
invasive diagnostic test performed by using the radionuclide 99mTc-technetium 
pertechnetate (Tc-99).  It has been used for the diagnosis of Sjogren’s syndrome, 
Bell’s palsy, sialolithiasis, gland aplasia and duct obstruction.  A gamma scintillation 
camera visually records the uptake, concentration and excretion of the pertechnetate 
anion by major salivary glands and other body organs.  Tc-99 is injected 
intravenously in the antecubital fossa and the camera immediately records at 60s 
/frame images with the exposure made every two minutes.  Fourty minutes after the 
injection, 0.5 mL of 2% citric acid is applied on the dorsum surface of the tongue and 
the study continued for additional 14 minutes.  The complete study consists of 27 
separate exposures which are then evaluated by the radiologists (Kohn et al., 1991).  
Sialography is radiographic imaging of the salivary gland ductal architecture after 
infusion of a contrast fluid through the salivary duct via a cannula.  Sialogram images 
may be used to diagnose sialectasia in Sjogren’s syndrome (Kalk et al., 2002).  Three-
dimensional magnetic resonance (3D-MR) sialography has proven beneficial to 
capture the salivary duct anatomy especially after radiation therapy and has potential 
use in the future since it can record submandibular and sublingual duct systems 
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simultaneously and thus is more efficient than a two-dimensional (2D) sialogram 
(Astreinidou et al., 2007).  Other imaging modalities such as salivary gland magnetic 
resonance imaging (MRI), plain radiographic films and ultrasonography are also used 
to detect salivary gland tumours or duct obstructions.  Minor salivary gland biopsy, 
usually taken from the labial aspect of the lower lip may be useful if Sjogren’s 
syndrome is included in the differential diagnosis.  The histopathological features of 
Sjogren’s syndrome are the presence of at least two foci (clusters of 50 lymphocytes 
in each foci) in a 4 mm x 4 mm tissue section obtained from the biopsy (Navazesh, 
2003).  Inflammatory changes may also be seen in the histopathological section, for 
example due to some medications and are usually reversible.  Blood tests of 
individuals to investigate the presence of specific anti-nuclear antibodies (ANAs) 
such as anti-SSA/Ro and anti-SSB/La and positive rheumatoid factor (RF) are 




Salivary hypofunction or hyposalivation is a condition with actual reduction in 
salivary flow due to medications, diseases or following radiation therapy to the head 
and neck (Nederfors, 2000; Tschoppe et al., 2010).  A consequence of dry mouth is 
increased risk of dental caries especially on flat surfaces.  Altered taste may cause 
patients to consume more sugar-containing food and beverages, thus contributing to 
the increased caries incidence (Guggenheimer and Moore, 2003).  Increased caries 
incidence is also associated with the reduced buffering capacity of saliva due to 
reduced salivary flow (Turner et al., 2007).  Oral candidosis and burning mouth 
syndrome are frequently seen in patients with hyposalivation (Jensena et al., 2006, 
Turner et al., 2007).  Saliva is important for oral health and aids in swallowing, oral 
cleansing, digestion and taste.  People with reduced salivary flow may have difficulty 
in chewing and swallowing food, especially dry foods.  Hyposalivation is also 
associated with taste disturbances that may lead to poor eating, causing a lack of 
nutritional support, especially in elderly patients.  They also have increased 
susceptibility to aspiration pneumonia  (Turner and Ship, 2007).  Individuals with 
hyposalivation may have difficulties with denture retention due to the lack of 
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lubrication and salivary film.  They may complain of halitosis, burning mouth, 
intolerance to spicy and acidic food and speech and eating difficulties.   
 
Xerostomia may result in an increased risk for clinical depression.  In a study done in 
the United Kingdom, using the Hospital Anxiety and Depression Scale (HADS) (a 
self-administered questionnaire to evaluate the presence and degree of anxiety and 
depression), an increased risk for clinical depression was found in patients with 
Sjogren’s syndrome (Stevenson et al., 2004).  A study done on radiotherapy patients 
with xerostomia showed a decrease in the quality of life, especially in female and 
younger patients that worsened with time (Jellema et al., 2007).  Another study done 
on elderly patients living in a long-term care facility showed that xerostomia alone 







Candida species are normal oral commensals (Cannon and Chaffin, 1999).  The most 
prevalent Candida species isolated from the oral cavity is Candida albicans (Cannon 
et al., 1995; Coronado-Castellote and Jiménez-Soriano, 2013).  C. albicans is a 
polymorphic organism because it can grow in yeast, hyphal and pseudohyphal modes 
and may produce chlamydospores in certain growth conditions (Odds, 1988 reviewed 
by Cannon and Chaffin, 1999).  In most individuals, the presence of C. albicans in the 
oral cavity does not indicate a disease.  C. albicans may cause two major types of 
infection; superficial infections such as oral or vaginal infections and life-threatening 
systemic infections (Mayer et al., 2013).  Commensal colonisation occurs when the 
population of C. albicans cells remains stable in the oral tissues without giving rise to 
clinical disease.  
 
Colonisation depends on the entry of cells into the oral cavity (acquisition), 
attachment and growth of the cells, tissue penetration and cells removal from the oral 
cavity (Cannon and Chaffin, 1999).  The rate of yeast cell entry into the oral cavity 
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versus the rate of removal determines whether Candida colonisation occurs or not.  
When tissue damage is present, candidosis is more likely to occur.  In order for 
Candida to colonise the oral cavity, a population must adhere to the host surface.   
This depends on the Candida cell wall and adhesins.  The cell wall of C. albicans not 
only provides a biological support for the organism, but is also important in the 
interactions with the human host.  Adhesins are the binding molecules that mediate 
the binding of C. albicans to other cells, inert polymers or proteins (Cannon and 
Chaffin, 1999).  In the oral cavity, Candida can adhere to the oral epithelial cells, 
saliva molecules and teeth.  They also adhere to the inert polymers of dental 
prostheses and other oral microorganisms.  In the mouth, C. albicans is primarily 
isolated from the posterior half of the dorsum of the tongue and secondarily from 
saliva and other sites of the oral cavity (Arendorf and Walker, 1980).  Adherence of 
Candida to the epithelial cells was higher in infants, children with oral infection or 
during antibiotic therapy, diabetic patients and in AIDS patients.  Candida growth 
was increased in the presence of glucocorticoids, dexamethasone or triamcinolone 
acetonide and was also affected by a rise in temperature (Cannon and Chaffin, 1999).   
 
Adherence to dental prostheses depends on hydrophobicity, the surface roughness of 
the prosthesis and the type of base material.  C. albicans is less hydrophobic 
compared to other species such as Candida tropicalis, Candida glabrata and Candida 
krusei.  The more hydrophobic species adhere more to inert polymers.  Acrylic bases 
promote less adherence than tissue conditioners and soft liners (Okita et al., 1991 
reviewed by Cannon and Chaffin, 1999).   Co-adherence of C. albicans with several 
oral bacteria is also reviewed by Cannon and Chaffin (1999), such as Streptococcus 
gordonii, Streptococcus mutans, Streptococcus oralis, Streptococcus sanguis, 
Streptococcus salivarius and Actinomyces species.  C. albicans adheres to adsorbed 
saliva molecules (saliva pellicles) using specific adhesins that recognise cryptitopes 
(cryptic receptors) to promote colonisation and prevent saliva-mediated aggregation 
and clearance from the oral cavity. 
 
The other important factor in oral colonisation is the growth of the Candida 
populations.  The cells need to grow and multiply to at least match the level of 
clearance.  C. albicans secretes aspartyl proteinases and hydrolytic enzyme N-
acetylglucosaminidase (hexosaminidase) that release carbon and nitrogen sources and 
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contribute to its growth and survival in the oral cavity.   Antibiotic therapy increases 
the growth rate of Candida cells because it lessens the competition for nutrients with 




The pathogenicity of C. albicans depends on several factors including polymorphism, 
adhesins, tissue invasion, biofilm formation, contact sensing and thigmotropism, 
secreted hydrolases, pH sensing and regulation, metabolic adaptation, environmental 
stress response, heat shock proteins and metal acquisition (Mayer et al., 2013).  C. 
albicans may grow as ovoid-shaped budding yeast, elongated ellipsoids with 
constrictions at the septa (pseudohyphae), or parallel walled true hyphae.  They may 
also be present as ‘white’ and ‘opaque’ cells, or chlamydospores.  Dimorphism is the 
transition between the yeast form and hyphal form (Mayer et al., 2013), also known as 
morphogenesis (Calderone and Fonzi, 2001).  Phenotypic switching is the change of 
the organism between the white and opaque form that is reversible and occurs rapidly 
(Calderone and Fonzi, 2001).  However, the role of phenotypic switching in C. 
albicans virulence is still unclear.  The hyphal form has been shown to be more 
invasive, but its presence is related to certain conditions such as high pH (pH>7), 
starvation, presence of serum or N-acetylglucosamine, physiological temperature and 
presence of carbon dioxide (CO2).  There are two mechanisms of invasion of C. 
albicans into the host cells; induced endocytosis and active penetration.  Induced 
endocytosis is a passive process where the fungus expresses specific proteins on the 
cell surface (invasins), particularly Als3, which triggers engulfment into the epithelial 
cells.  Active penetration is an active process by viable C. albicans hyphae.  
Adhesins, namely agglutinin-like sequence (ALS) proteins are upregulated during C. 
albicans infections (Mayer et al., 2013), in particular Als3 during hyphae formation 
(Gow and Hube, 2012).  Tissue damage may also occur due to hyperactivity of the 
immune system, for example massive infiltration of neutrophils (Gow and Hube, 
2012).  Secreted enzymes are also found to be responsible for the pathogenicity of C. 
albicans; secreted aspartyl proteinases (SAP) and phospholipases (PL), including nine 
SAPs and four PLs (Calderone and Fonzi, 2001). 
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The process of biofilm production involves adherence of yeast cells to substrates, 
proliferation of yeasts, formation of hyphal cells, accumulation of extracellular matrix 
and dispersion of yeast cells from the biofilm complex.  Mature biofilm are more 
resistant to antimicrobial agents and host defence factors.  It is proposed that β-
glucans in the extracellular matrix protect the C. albicans from being attacked by 
neutrophils (Mayer et al., 2013).  When C. albicans cells come in contact with a solid 
surface, contact sensing occurs and triggers switching of the fungus into the hyphal 
form and induces biofilm production.  Thigmotropism is when there is a specific 
structure on the surface (for example ridges) that causes directional hyphal growth. 
Hydrolytic enzymes are secreted when C. albicans cells adhere to host cells.  These 
enzymes can facilitate the invasion of C. albicans into cells. Glucose is the main 
carbon source for C. albicans.  It can metabolise glucose in the blood stream via 
glycolysis and gluconeogenesis, especially in systemic candidosis.  C. albicans is able 
to utilise host lipids, proteins, amino acids and phospholipids.  C. albicans is capable 
of adapting to the environmental stresses.  There are several stress response pathways 
including heat-shock, osmotic, oxidative and nitrosative.  Heat-shock proteins 
facilitate the adaptation of C. albicans to thermal stress via trehalose production and 
prevent the protein unfolding that induces cell death.  The osmotic stress response 
induces the accumulation of glycerol to prevent loss of water due to the outward-
directed chemical gradient.  The oxidative stress response induces detoxification of 
reactive oxygen species such as peroxide, superoxide anions and hydroxyl radicals.  
Trace metals including iron, zinc, manganese and copper are important for the growth 
and survival of all living cells.  C. albicans acquires trace metals from the host via 
siderophores and transporters (Mayer et al., 2013). 
 
The cell wall composition of C. albicans is 90% carbohydrate and 10% protein.  The 
fibrillar outer layer consists of mannoproteins, while the β-glucans/chitin layer lies 
underneath the mannoprotein, with both providing strong support to the cell wall 
(Gow and Hube, 2012).  The outer cell wall consists of mannans that are less 
structured and permeable thus affecting the cell resistance against antifungal agents.  
The carbohydrate in the cell walls not only induces the immune response of the host, 
but also induces hyperactivity of the inflammatory response causing pathogenicity of 
the C. albicans.  The transition of C. albicans from colonising organism into 
pathogenic organism involves multiple complex pathways (Gow and Hube, 2012).   





In general, the number of Candida cells in the oral cavity is inversely affected by 
salivary flow.  One of the reasons for this is the antimicrobial property of saliva.  The 
number of C. albicans and Candida parapsilosis colony forming units (CFU) isolated 
from individuals with decreased salivary flow is high compared to individuals with 
normal salivary flow (Torres et al., 2003; Torres et al., 2002).  Table 1.2 summarises 
studies quantifying the median Candida CFU/mL in participants with decreased 
salivary flow (median C. albicans CFU/mL in individuals with normal salivary flow 







































































C. albicans >500 Not stated 
Table 1.2 Studies of Candida cfu in participants with decreased salivary flow (CS = 
chewing-stimulated whole; UW = unstimulated whole; ASP = acid-stimulated 





Patients on long-term phenothiazine therapy were found to have a higher frequency of 
Candida infection and higher mean number of Candida CFU than a control non-
psychiatric group (Lucas, 1993).   The first reported case of oral Candida infection in 
a patient receiving chlorpromazine was in 1962 (Kane, 1963) where a patient on a 
high dose of chlorpromazine was described as having a brown hairy tongue and 
severe pharyngitis and glossitis due to C. albicans infection.  The condition improved 
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when the patient was prescribed with 100,000 units of Mycostatin suspension four 
times a day.  Chlorpromazine was continued but at a reduced dose.  There is a lack of 
evidence in the literature that directly correlates oral Candida infections to 
antipsychotic drug intake.  One of the correlations of oral Candida infection in 
patients taking antipsychotic medications is increased susceptibility due to dry mouth 
as an adverse effect of the medications.  Another factor that may contribute to oral 
fungal infections when an individual is treated with antipsychotic medications is 
hyperglycaemia.  Some antipsychotic medications such as chlorpromazine, 
fluphenazine, clozapine, olanzapine and quetiapine increase blood glucose levels 
(reviewed by Arulmozhi et al., 2006).  However, the correlation between oral 
candidosis and higher glucose levels such as in diabetes mellitus, depended on other 
local factors as well.  This included glycaemic control level, denture-wearing, 
hyposalivation, defective candidacidal activity of neutrophils and tobacco smoking 
(Soysa et al., 2006). 
 
While the natural host defence mechanisms against Candida infection are weakened 
by the xerostomia induced by antipsychotic medication, an in vitro study of 
phenothiazines, specifically chlorpromazine and trifluoperazine, showed an inhibition 
of C. albicans growth (Sharma et al., 2001) and other Candida species including C. 
tropicalis, C. parapsilosis and C. glabrata (Afeltra and Verweij, 2003) suggesting 
these medications have some antifungal activity.  




Factors predisposing to Candida carriage include drug therapy, especially broad-
spectrum antibiotics, immunomodulatory and xerogenic medications, blood 
dyscrasias and malignancy, dietary factors, endocrine disorders, immunologic 




The systemic health of the individual affects C. albicans colonisation.  It was found 
that 40% to 60% of healthy adults harbour Candida in the oral cavity without signs 
and symptoms of candidosis (Zegarelli et al., 1993 reviewed by Soysa et al., 2006).  
Clinically, there are some factors that predispose to oral candidosis including drug 
therapy, especially broad-spectrum antibiotics, immunomodulatory and xerogenic 
medications, blood dyscrasias and malignancy, dietary factors, endocrine disorders, 
immunologic disorders and salivary changes (Farah et al., 2000).  Drug therapy, 
including broad-spectrum antibiotics, immunomodulatory medications and cytotoxic 
medications, alters the host susceptibility, resulting in oral candidosis (Cannon et al., 
1995).  Individuals with diabetes were found to have higher Candida carriage rate 
than the non-diabetics, presumably due to increased Candida growth with high 
glucose levels in saliva and decreased pH (Soysa et al., 2006).  Reduced phagocytosis, 
intracellular killing, bactericidal activity and chemotaxis in poorly controlled diabetes 
might increase the susceptibility of diabetic patients to oral Candida infection (Soysa 
et al., 2006). Furthermore, denture wearers with diabetes had higher Candida carriage 
rate due to the dentures inducing biofilm formation, acting as an additional reservoir 
for the Candida colonisation and infection (Soysa et al., 2006).   
 
Medications predisposing to oral candidosis were antimicrobials, including excessive 
use of antibacterial mouthwashes and corticosteroids (topical, systemic and 
aerosolised) (Farah et al., 2000).  The number of yeasts was found to be higher in 
patients who had undergone radiation therapy to the head and neck with subsequent 
xerostomia (Ramirez-Amador et al., 1997).   Individuals with an impaired immune 
system, such as patients with myeloproliferative diseases or malignant diseases were 
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found to have a higher incidence of oral fungal infections.  Deficiency in certain 
nutrients such as iron, folic acid and vitamins may predispose to oral candidosis.  
Diseases that cause immunodeficiency such as acquired immune deficiency syndrome 
(AIDS), severe combined immunodeficiency syndrome (SCID), hereditary 
myeloperoxidase deficiency and Chediak-Higashi disease may predispose to oral 
candidal infections.   
   
1.4.5.2	Local	factors	that	promote	oral	candidosis	
 
Local factors that predispose to oral candidosis include irritation from ill-fitting 
dentures and poor oral hygiene (Farah et al., 2000).  Poor denture hygiene such as 
wearing the dentures continuously without taking them out at night and poor denture 
cleanliness predisposes the individuals to denture-related oral candidosis. The 
continuous irritation from ill-fitting dentures may cause invasion of the organisms 
through the microscopic breaks in the oral mucosa.  The yeast counts in denture 
wearing persons were found to be about ten-fold higher when compared to healthy 
individuals (Samaranayake et al., 1990 reviewed by Farah et al., 2000).  Candida 
biofilms play a role in denture-induced stomatitis especially on dentures rough 
surfaces due to better adhesion of the organisms and the resistance to cleaning 




Clinically, oral candidosis may present as pseudomembranous candidosis, 
erythematous candidosis, hyperplastic candidosis, denture-associated erythematous 
candidosis, angular cheilitis, median rhomboid glossitis and chronic mucocutaneous 
candidosis (Napeñas et al., 2009; Farah et al., 2010). To aid in making a clinical 
diagnosis for oral candidosis, staining of cytological smears from affected areas with 
periodic acid-Schiff (PAS) may be used to detect hyphal and yeast cells.  A tissue 
biopsy may be useful for suspected chronic hyperplastic candidosis (Jensena et al., 
2006).  Sabouraud’s medium can be used to determine CFU and commercial 
investigation kits such as Oricult N (produced by Orion Diagnostica) may be useful.  
  




Pseudomembranous candidosis or thrush is the most common presentation of oral 
candidosis (Cannon et al., 1995).  It presents clinically as confluent whitish-yellow 
creamy or yellow velvety plaques on the surfaces of the oral mucosa (Reichart et al., 
2000; Farah et al., 2010).  When the superficial material is wiped off, it reveals an 
erythematous surface that may easily bleed.  Pseudomembranous candidosis may 
become painful with a burning mouth sensation, sour taste or altered taste sensation 
and discomfort or bleeding when it is symptomatic (Sharon and Fazel, 2010). 
Treatment with antifungals is usually indicated especially in immunocompromised 
patients to prevent oesophageal involvement and recurrent infections (Reichart et al., 
2000; Williams and Lewis, 2011).  In a debilitated patient, it may spread 
oesophageally and/or involve angular cheilitis (McCullough and Savage, 2005). 
 
A biopsy is not usually taken to make the diagnosis of pseudomembranous candidosis 
and the diagnosis is made on the basis of the characteristic clinical features and the 
presence of numerous Candida hyphae on a smear.  The host epithelium is destroyed 
by proteinases, lipases and other enzymes contained at the tip of the penetrating 
hyphae.  Microabscesses are produced when Candida hyphae destroy the desmosomal 
bridges, thus opening the intercellular space for invasion of inflammatory cells.  
Enzyme activity produces microcavities that become the space for focal aggregates of 
polymorphs, thus producing microabscesses (Fisker et al., 1982 reviewed by Reichart 
et al., 2000).  The pseudomembrane comprises necrotic material, food debris, 
leukocytes, bacteria and fungi.  Acanthosis in the deeper layers of the epithelium with 
lymphocytic infiltrate in the surrounding connective tissue may be present in some of 
the plaques (Farah et al., 2000).  This feature is commonly found in 
immunocompromised patients, elderly people, poorly controlled diabetes mellitus 
patients, HIV patients, and patients receiving corticosteroid therapy, anti-proliferative 
therapy, psychotropic medications and long-term broad-spectrum antibiotic therapy 
(McCullough and Savage, 2005).  In an immunocompetent individual, the 
inflammatory infiltrate may be reduced with a thicker pseudomembrane and rarely 
penetrate deeper to the spinous cell layer (Reichart et al., 2000).   
 




The clinical presentation of erythematous candidosis (previously known as atrophic 
candidosis) is localised erythema of the oral mucosa.  It is uncommon and may be 
associated with corticosteroids, broad-spectrum antibiotics (topical and systemic) or 
human immunodeficiency virus (HIV) infections (Scully et al., 1994).  It may appear 
with or without symptoms.  The common sites for this lesion are the dorsum of 
tongue, the palate and less commonly the buccal mucosa (Reichart et al., 2000).  
Previously, it was known as antibiotic sore mouth.  It appears as a well-circumscribed 
erythematous lesion (Reichart et al., 2000) or depapillated area (Scully et al., 1994) on 
the dorsum surface of the tongue, sometimes concomitant with a palatal lesion.  It 
may mimic denture stomatitis Type I and Type II (Newton’s classifications) where 
pin-point erythematous patches on palate or erythema on the mucosa of the denture 
bearing area may appear (Reichart et al., 2000).  Antifungal therapy is always needed 
along with correction of the underlying predisposing factor (Reichart et al., 2000).   
 
Histologically, it may appear with epithelial atrophy or lack of a keratinised surface 
layer (Eversole et al., 1997; Romagnoli et al., 1997; Reichart et al. 2000) although a 
biopsy is not usually required for diagnosis.  It does not usually show hyphal 
infiltration of the epithelium.  However, yeast may be found superficially on the 
epithelial surface.  The erythema may be associated with increased mucosal 




Hyperplastic candidosis presents as a chronic, well-demarcated, slightly raised, 
adherent white lesion of the oral mucosa.  The terms previously used for this lesion 
are hyperplastic candidosis, Candida-associated leukoplakia or Candida leukoplakia 
(van der Waal, 1997).  It ranges from small, translucent lesions to large, dense 
opaque, hard and rough on palpation, plaque-like lesions (Scully et al., 1994).  There 
are two variants of this condition; isolated (homogenous form) and multiple white 
nodules on an erythematous background (nodular or speckled form), often 
symptomatic.  It is most commonly found on the post-commisural buccal mucosa 
(Scully et al., 1994).  It is generally found in tobacco smokers (Reichart et al., 2000).  
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Other less common locations are the tongue and the palate just posterior of the upper 
denture margin.  This type of infection has been associated with a risk for dysplasia 
and malignant change (McCullough and Savage, 2005; Williams et al., 2008).  
 
Histological features include infiltration of Candida hyphae in the superficial strata of 
the epithelium.  Inflammatory cells may be found in the hyperplastic and acanthotic 
epithelium with the appearance of microabscesses (Reichart et al., 2000).  It is crucial 
that the presence or absence of tissue dysplasia be determined from the biopsy and the 




Denture-associated erythematous candidosis (chronic atrophic candidosis, denture 
sore mouth, Candida-associated denture stomatitis) is a common inflammatory oral 
mucosal lesion that appears on the mucosa in contact with the fitting surface of a 
denture.  Clinically, it presents as erythematous and oedematous mucosa confined to 
the area of the fitting surface of the denture (Lynch, 1994; Samaranayake et al., 
2002).  The severity ranges from petechiae to generalised inflammation with papillary 
hyperplasia (Barbeau et al., 2003).  It is frequently asymptomatic, but patients may 
experience slight soreness or a burning sensation (Scully et al., 1994).  The primary 
aetiology of this lesion is the overgrowth of Candida due to the restricted salivary 
flow underneath the denture surface, especially on the palate (Samaranayake et al., 
2002).  Other contributing factors include poor oral and denture hygiene, wearing 
dentures at night, ill-fitting dentures (Farah et al., 2010), bacterial infections, 
mechanical irritation and allergic reaction to the denture base material (Samaranayake 
et al., 2002). Newton AV, 1962 reported three subtypes of Candida-associated 
denture stomatitis depending on the severity of the lesion;  
Type I  :  localised simple inflammation or pin-point hyperemia  
Type II : a diffused presentation of erythematous or generalised simple type  
  involving part of or entire denture bearing mucosa 
Type III: granular or papillary type commonly involving the midline of hard  
   palate and alveolar ridge 
 




Angular cheilitis (angular stomatitis, angular cheilosis) is a chronic inflammatory 
lesion that affects the angles of the mouth.  Clinically, it appears as erythematous, 
fissured lesions at the corners of the mouth, usually asymptomatic and bilateral 
(Samaranayake et al., 2002; Farah et al., 2010).  One of the contributing factors is 
lack of soft tissue support or reduced vertical facial height especially in edentulous 
patients or denture wearing patients (Scully et al., 1994).  The folded and wrinkled 
tissue at the corners of the mouth allows saliva accumulation thus a chronic moist 
environment for harbouring Candida and bacteria for example Staphylococcus and 
Streptococci is produced.  Angular cheilitis may be associated with anaemia, vitamin 





The clinical presentation of this lesion is an area that is symmetrical, erythematous, 
elliptical or rhomboid-like on the posterior dorsal surface of the tongue, just anterior 
to the circumvallate papillae (Samaranayake et al., 2002).  The atrophy is due to 
atrophic filiform papillae.  Under the microscope, the hyperplastic rete pegs of the 
fungal hyphae extend into the corium, thus invading the superficial layers of 




When there is a persistent or recurrent Candida infection on the skin, nails and extra-
oral mucosa, about 90% of these cases also have oral candidosis and this syndrome is 
known as chronic mucocutaneous candidosis (Odds, 1988).  It is associated with a 
defect in cell-mediated immunity and a variety of primary immunodeficiencies such 
as Nezelof syndrome (thymic alymphoplasia), DiGeorge syndrome (congenital 
thymic aplasia), hyperimmunoglobulin E syndrome, myeloperoxidase deficiency and 
endocrinopathies may be associated (Tarcin, 2011).   
 




The diagnosis of oral candidosis should be made from comprehensive medical and 
history taking.  The patients’ complaints should be investigated accordingly.  Proper 
examinations of the signs that presented with the symptoms are crucial in order to 
make differential diagnosis, followed by additional investigations either non-surgical 
or surgical.  Clinical laboratory procedures including PAS staining for investigations 
of the presence of Candida hyphae from cytological smears can usually confirm the 
diagnosis of pseudomembranous candidosis (Farah et al., 2000).  However, in the 
denture-induced erythematous candidosis, Candida hyphae are not usually present 
(Farah et al., 2000).  Swabs taken from the mucosal tissues followed by culturing are 
more useful in this condition.  Investigating the oral Candida carriage rate may also 
be useful, where 50% of the population have less than 1,000 CFU/mL Candida 
compared to infected individuals with 4,000 to 20,000 CFU/mL of Candida 
population (Farah et al., 2000).  Immunohistochemical techniques may identify the 
Candida species present, whilst media such as CHROMagar™ may identify the types 
of Candida based on their colony colour.  This procedure may become necessary 
when the routine treatment of oral candidosis failed or when the patient is 
immunocompromised.  Biopsy provides the most accurate diagnosis for chronic 
hyperplastic candidosis or median rhomboid glossitis (Farah et al., 2000). 
 
Blood tests for patients with oral Candida infections may reveal abnormal 
haematological or immunological results.  For example, patients with chronic 
mucocutaneous candidosis may have endocrinopathies or defects in the immune 
system, patients with angular cheilitis may have iron or vitamin deficiencies.  When 
making a diagnosis of oral candidosis, the clinicians should exclude other oral 
mucosal lesions such as chemical burns, traumatic ulcers, mucous patches of syphilis, 
white keratotic lesions, thermal burns, drug reactions, erosive lichen planus, discoid 




Oral candidosis can be treated with a range of antifungal medications (Ellepola and 
Samaranayake, 2000).  Topical treatment with antifungal agents should be the first 
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line of treatment for oral candidosis.  However, if the oral candidosis is complicated 
with systemic involvement, systemic treatment with antifungal agents should be 
considered.  There are two main groups of antifungal agents; the polyene macrolides 
(for example nystatin and amphotericin B) and azole derivatives (examples are 
clotrimazole, ketoconazole, miconazole and fluconazole). In order to successfully 
treat oral candidosis, oral hygiene measures, denture hygiene (when applicable) and 
adjunct use of antiseptic mouthwashes such as chlorhexidine should be considered 
(Jørgensen, 1990).  Patients with severe Candida infections, may need hospitalisation 
and treatment with systemic antifungals such as fluconazole, itraconazole and 
amphotericin B.  Fungal infections from the oral cavity may spread along the 
gastrointestinal tract; isolates from the oral environment were found similar to the 
isolates from faeces in individuals with denture stomatitis (Bergendahl et al., 1979).      
 
Antifungal medications may act by reducing the adherence of Candida to epithelial 
cells, changing the cell-surface charge or affecting the wall and membrane 
biosynthesis and structure (Cannon and Chaffin, 1999).  There are several chemical 
classes of antifungal medications with different cellular targets.  Polyenes such as 
amphotericin B and azoles such as fluconazole, itraconazole, and ketoconazole are the 
two main classes of antifungals.  Other classes of antifungals not effective in treating 
Candida albicans infections are allylamines (terbinafine) and morpholines 




The mechanism of action of polyenes is mainly by binding tightly to the ergosterol 
molecules (the principal sterol in fungal membranes) and forming annuli thus 
damaging the cell plasma membrane resulting in a leakage of intracellular ions 
(Sanglard et al., 2003; Odds et al., 2003).   However, the definite mechanism of action 
is still unclear (Odds et al., 2003).  Polyenes are toxic to mammalian cells because of 
low selective affinity towards ergosterol and interactions with cholesterol.  
Amphotericin B is a polyene antifungal agent administered systemically to treat 
visceral infections (Odds et al., 2003).  Nephrotoxicity is one of the toxic effects of 
amphotericin B, but newer formulations are being developed to overcome this (Odds 
et al., 2003).	 	 In some countries, Amphotericin B is used in lozenge form to treat 
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candidosis.	 	Nystatin is a polyene derivative produced by Streptomyces albidus and 
Streptomyces noursei.  It is only used as a topical agent due to severe toxicity when 
administered intravenously and is ineffective when taken orally.  It is available in 
ointment, cream and powder form for cutaneous use; and in liquid, suspension and 
pastille form for the treatment of oral candidosis (Zhang et al., 2007).  Nystatin 
ointment is useful for application to denture surfaces to treat denture associated 




Azole antifungals are synthetic compounds with one or more 5-membered ring (each 
ring contains either two or three nitrogen atoms).  Imidazole rings contain two 
nitrogen atoms, while triazole rings contain three nitrogen atoms (Lyman and Walsh, 
1992).  The mode of action is via the inhibition of cytochrome P450 enzymes, thus 
blocking the biosynthesis of ergosterol.  They interact with the fungal enzyme 
lanosterol 14-α demethylase causing reduction in the ergosterol content of membranes 
resulting in the inhibition of fungal growth and replication.  Azoles are mainly 
fungistatic, except in higher concentrations when they become fungicidal (Zhang et 
al., 2007).  Examples of imidazole antifungals are clotrimazole, miconazole and 
ketoconazole.  Itraconazole and fluconazole are triazoles.  The most commonly used 
azole is fluconazole.  Fluconazole belongs to the newer category, bis-triazole 
antifungal drug and is only used systemically (Jørgensen, 1990).  Fluconazole has 
advantages such as excellent oral bioavailability, stable parenteral formulation and 
fewer drug interactions when compared to other azoles (Marchetti et al., 2000).  The 
choice of treatment depends on the patient’s medical history, oral symptoms, severity 
of infection and the level of compliance expected.  Cautious use of fluconazole in 
patients with impaired mental state should be practised because these patients may 
deteriorate further (Lyman and Walsh, 1992).  An oral suspension of fluconazole (5 
mg/mL) is a topical alternative to the traditional nystatin oral suspension (100 000 
IU/mL) for the treatment of oral candidosis (Tarcin 2011).  Clotrimazole may also be 
used twice daily for the treatment of oral candidosis; available in spray or lozenge 
forms (Zhang et al., 2007).  
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Recent investigations found a risk for hospitalisation due to gastrointestinal (GI) 
bleeding when oral azoles are prescribed to warfarin users (Purkins et al., 2003; 
Holbrook et al., 2005; Schelleman et al., 2008).  Fluconazole for example increases 
the international normalised ratio (INR) up to 38% in previously stable patients, while 
itraconazole and variconazole significantly prolonged the prothrombin time in 
patients taking warfarin (Shakeri-Nejad and Stahlmann, 2006).  Topically applied 
miconazole oral gel and nystatin oral gel were found to interact equally with warfarin 
by impairing the metabolism of warfarin and causing an elevation in the INR	 in 
previously stable patients, predisposing the patients to major bleeding complications 
(Kovac et al., 2012).  In order to avoid these complications, other alternatives to 





Treatment failure can arise, however, if the yeast responsible for the candidosis 
develops antifungal drug resistance.  Resistance to imidazoles and triazoles, 
particularly fluconazole, is more common than to polyenes, allylamines and 
echinocandins (Cannon et al., 2009).  Host factors that predispose to azole resistance 
are immunocompromised, including HIV infection or in bone marrow transplant 
patients undergoing immunosuppressive therapy and repeated or long term use of 
azole antifungals (White et al., 2002; Sanglard et al., 2003).   
 
There are multiple mechanisms of azole resistance in C. albicans including mutations 
in the gene ERG11 involved in ergosterol biosynthesis and the overexpression of drug 
efflux pumps (White et al., 2002).  ATP-binding cassette (ABC) pumps and the major 
facilitator superfamily (MFS) transporters are the two main families of the efflux 
protein.  Azoles target the 14α-demethylase enzyme encoded by ERG11, blocking 
ergosterol biosynthesis.  This leads to depletion of ergosterol, thus inducing the 
accumulation of intermediates from the toxic sterol pathways, which inhibit growth 
(reviewed by Ramage et al., 2012).  High-level azole resistance is caused by the 
overexpression of ABC efflux pumps in the plasma membrane (White et al., 2002; 
Cannon et al., 2009).  The transmembrane ABC efflux proteins Cdr1p and Cdr2p 
from C. albicans expel hydrophobic molecules out of the cells using energy from 
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ATP hydrolysis.  The overexpression of these transporters plays a major role in 
developing antifungal drug resistance, mainly to azoles (Akins, 2005) by reducing the 
intracellular azole concentration.  Interestingly, expression of these ABC efflux 
pumps is induced in C. albicans cells by the antipsychotic fluphenazine (de Micheli et 
al., 2002; Coste et al., 2004; Manoharlal et al., 2011).   
 
Another important factor in azole resistance is biofilm production on host tissues by 
C. albicans (Cannon et al., 2009).  These biofilms are resistant to azole antifungal 
agents.  Biofilms are defined as an enclosed extracellular matrix (ECM) containing 
highly structured communities of microorganisms, either attached to the surface or 
attached to one another (review by Ramage et al., 2012).  Microorganisms that 
produce biofilms have advantages such as protection from the environment, resistance 
of physical and chemical stress, metabolic cooperation and community-based 
regulation of gene expression.  ABC efflux pumps were thought to express at early 
stages of biofilm formation.   
 
Although still somewhat controversial, particularly from a clinical standpoint, in vitro 
experiments using phenothiazines such as chlorpromazine and trifluoperazine resulted 
in some growth inhibition of C. albicans (Buchan et al., 1993; Sharma et al., 2001). 
Phenothiazines and also fluphenazine are calmodulin inhibitors.  Calmodulin is a 
calcium binding protein involved in fungal proliferation.  Buchan et al, (1993) 
concluded that although there was growth inhibition of C. albicans in mice treated 
with trifluoperazine, the dose was too large (more than 25 mg/kg per dose) to be 
considered of therapeutic value.  Stylianou et al. (2014) compared the minimum 
inhibitory concentration (MIC) of haloperidol (MIC, 0.38 µg/mL) and trifluperidol 
(0.4 µg/mL) and found that they exhibited a comparable antifungal activity towards 
C. albicans as fluconazole (MIC value of 0.3 µg/mL).  
 
Thus the prescription of certain antipsychotics for mental illness may have 
consequences for oral health. They may have an antifungal effect, or they may induce 
azole resistance in C. albicans due to induction of ABC pump expression. These are 
important considerations that warrant further investigation. 
 




The particular interest of this study is to investigate oral Candida carriage and 
antifungal susceptibility of Candida albicans isolates in patients receiving 
antipsychotic medications.  Specific objectives of this study is to determine the level 
of colonisation with Candida of the oral mucosae in people taking antipsychotic 
medications when compared to healthy controls and to xerostomic individuals not 
prescribed with antipsychotics.  The other objectives are to determine the Candida 
species present in their saliva samples and also to measure the azole resistance of 
these isolates.  The final aim of this study is to determine whether the antipsychotic 









MATERIALS AND METHODS 






Ethical approval was obtained from the University of Otago Human Ethics 
Committee (committee reference number 12/207) prior to the recruitment of 







A convenience sampling of patients attending the Special Care Unit, of the University 
of Otago, Faculty of Dentistry was undertaken.  Patients were approached to consider 
participating in this research based on specific criteria.  The inclusion criteria for 
selecting participants for this study were: 
a) Patients aged between 20 and 70 years old 
b) Currently taking antipsychotic medications 
c) Known smoking status 
d) Living independently or with minimal supervision/support 
 
 
A list of potential participants was prepared from the list of patients registered in the 
Special Care Unit.  The patients’ recall cards in the Special Care Unit were examined.  
Some of the recall cards had a summary of the patient’s medical condition or 
disability written on them.  Fifty names were obtained from the recall cards, where 
their cards had “psych problems” written on them.  The clinical files of potential 
participants were obtained from the records office and carefully examined.  Patients 
with a history of intellectual disability or an inability to cooperate in the dental chair 
were excluded from the list of potential participants.  Other exclusion criteria 
included: 
a) Medically compromised individuals with conditions known to affect 
Candida carriage such as diabetes mellitus  
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By considering the inclusion and exclusion criteria, fifteen patients were found to be 
suitable for the research.  The patients were contacted by phone with a brief 
explanation about the study and invited to participate.  Nine patients agreed to 
participate in this study.   
 
Patients were provided with an information sheet (Appendix III) to read either before 
they came to the research appointments or on the appointment day itself.  They were 
given opportunities to ask questions if they needed to.  Information about this 
research was explained carefully to them either by the author or by their 
accompanying caregiver.   They understood that they could withdraw anytime from 
this study.  Signed consent forms were obtained from the participants.  Current 
smoking status was recorded.  The ethnicity of each participant and their age at 




Samples from two matched control groups (patients with xerostomia taking no 
antipsychotic medication, n=9 and healthy individuals with no history of xerostomia, 
n=9) had already been obtained for a different study performed by Leanne Xiao Li 
Hou for her Doctor of Clinical Dentistry degree titled “Oral yeast carriage and 
salivary protein profiles in xerostomia subjects and in age- and gender-matched 




A validated measure, the Xerostomia Inventory (XI) was used in this research to 
quantify xerostomia symptoms in study participants (Thomson et al., 1999). All 
participants answered eleven questions about symptoms of dry mouth.  The main 
question was “how often does your mouth feels dry?”, followed by eleven more 
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specific questions.  Four answering options were given for each question; ‘never’, 
‘occasionally’, ‘frequently’, ‘always’ (Table 2.1).   
 
How often does your mouth 
feels dry? 
Never Occasionally Frequently Always 
My mouth feels dry     
I have difficulty in eating dry 
food     
I get up at night to drink     
My mouth feels dry when 
eating a meal     
I sip liquids to aid in 
swallowing food     
I suck sweets or cough lollies 
to relieve a dry mouth     
I have difficulties in 
swallowing certain foods     
The skin of my face feels dry     
My eyes feel dry     
My lips feel dry     
The inside of my nose feels 
dry     
Table 2.1 Xerostomia Inventory (XI) 
 
Each answer was given a score: 1 for ‘never’, 2 for ‘occasionally’, 3 for ‘frequently’ 
and 4 for ‘always’.  The total score for the answers to all the questions was calculated.  
The total theoretical score ranged from 11 to 44.  This method gives an overview of 
the individuals’ experience of, and behaviour with, xerostomia.  The answering 
patterns of the participants were analysed to evaluate the severity of their xerostomia 
condition.  The frequency of xerostomia was analysed by comparing the mean XI 






All participants underwent a thorough clinical examination.  Oral soft tissues were 
inspected.  Any clinical evidence of candidosis in the mouth, for example 
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pseudomembranous candidosis, erythematous candidosis, median rhomboid glossitis 
or angular cheilitis (Napenas et al., 2009) either on the buccal mucosa, tongue or 
palate was recorded.  Signs of dry mouth were recorded, including: frothy saliva; dry 
shiny mucosa; depapillated or red, fissured, tongue; lack of saliva pooling in the floor 
of the mouth; and the mouth mirror sticking to the buccal mucosa.  The denture status 
of all participants was recorded.  Denture fitting surfaces were examined for evidence 




Three smears were taken from each participant by gently rubbing a sterile stainless 
steel flat plastic instrument against the oral tissues.  The smears were taken from the 
right and left buccal mucosa and the tongue.  Whenever there was evidence of 
Candida infection elsewhere in the mouth, further smears were taken.  The material 
obtained on the instrument was smeared onto glass slides.  All slides were labeled 
with the participant’s name, date of birth and the site from which the smears were 
taken. They were placed in a transporting laboratory bottle containing 95% ethanol, 
and sent to Medlab Dental Oral Pathology laboratory (Faculty of Dentistry, 
University of Otago).  Each participant was assigned with a laboratory registration 




In this study, oral rinse samples were collected from participants by asking them to 
pour 10 mL of water from a sterile pathology pot in their mouths, swish it around for 
30 s and then to expectorate the water mixed with saliva back into the specimen 
bottles.  The oral rinse samples were taken to the PC2 Molecular Biosciences 












Procedures for rapid periodic acid-Schiff (PAS) staining were performed on the 
smears to determine whether C. albicans was present.  The smears were fixed upon 
delivery to the laboratory because they had been soaked in 95% ethanol for about 1 h.  
Immediately upon receipt at the laboratory, the smears were rinsed with distilled 
water and then flooded with 1% fresh aqueous periodic acid for 3 min.  They were 
then washed under running tap water for another 3 min.  The smears were stained in 
Schiffs reagent for 10 min.  After that, the smears were washed with hot running tap 
water for 5 min.  They were then lightly counterstained with Gill’s haematoxylin for 
30 s followed by dipping them 10 times in Scott’s tap water for blue stain.  Finally, 
the smears were washed in tap water for 1 min and dehydrated before they were 
mounted.  Under the light microscope, fungi appeared magenta and nuclei were blue. 
 
The smears were examined using a light microscope where all material on the slide 
was viewed in a systematic manner from one end of the slide to the other, under low 
magnification (4x and 10x lens) initially, and with higher power (20x and 40x lens) 
for examination of possible hyphae and yeast cells.  In this study, PAS staining was 
used to detect the presence of Candida.  If hyphae were observed the smear was 
recorded as being positive for C. albicans.  Other Candida species such as C. glabrata 
will be PAS positive but they will not show the hyphal form, and appear in the 




CHROMagar™ Candida (Figure 2.1) agar plates were used as the primary isolation 
medium due to the ease of recognising Candida species via their colony colour on the 
agar plates.  CHROMagar™ Candida medium contains chromogenic chemicals that 
allow the rapid presumptive identification of Candida species. Different Candida 
species form colonies with different colours on this agar.  For example, C. albicans 
colonies are green, Candida tropicalis colonies are blue with a pink halo or blue-grey 
colony with a dark halo of brownish purple (Odds et al., 1994) and Candida krusei 
Chapter 2: Materials and Methods 
	 58	
colonies are pink with a downy appearance (Barasch et al., 2004; Birinci et al., 2004).  
Candida glabrata colonies vary from purple to pale pink (Beighton et al., 1995). 
 
The oral rinse samples were gently mixed before volumes of 100 µL and 200 µL were 
plated onto separate CHROMagar™ Candida plates.  The rest of the oral rinse sample 
was poured into a 15 mL tube and then centrifuged at 3000 × g for 5 min.  The 
supernatant was poured back into the specimen bottle and the pellet was resuspended 
in the remaining liquid using a vortex mixer and then plated onto a third 
CHROMagar™ Candida plate.  After the plates had been incubated at 37°C for 48 h 
they were removed from the incubator and examined for any Candida growth.  The 




Figure 2.1 Image taken from product leaflet on the website (www.chromagar.com) 
 
The number of colony-forming units (CFU) per oral rinse for each species was 
calculated from the number of colonies on the plates and the volume of the oral rinse 












The yeasts used in the antifungal susceptibility assays were fresh clinical isolates of 
C. albicans grown from the patients’ saliva samples.  Two yeast colonies were chosen 
for each Candida species present on each patient’s CHROMagar™ Candida plates 
(that showed Candida colonies) and subcultured onto Sabouraud dextrose agar (SDA) 
(Fort Richard Laboratories Ltd., New Zealand).  The plates were incubated at 37°C 
for 48 h.  Isolates were stored in yeast extract, peptone and dextrose (YPD) medium 
with 15% (w/v) glycerol at -80°C until further use. 
 
RPMI 1640 (Sigma-Aldrich Corporation, St. Louis, Missouri, USA) buffered with 
MOPS (3-(N-morpholino) propanesulfonic acid, Sigma-Aldrich Corporation) was 
used as the culture medium for yeast susceptibility testing.  RPMI liquid medium was 
prepared by dissolving 5.15 g RPMI 1640 powder and 17.3 g MOPS powder in 
distilled water, then the mixture was adjusted to pH 7 by adding sodium hydroxide 
(NaOH).  The volume was then made up to 300 mL with distilled water.  The RPMI 
1640/MOPS mixture is referred to as RPMI in this thesis. RPMI agar plates were 
prepared by adding 7.5 g agar (Oxoid Ltd., Wade Road, Basingstoke, Hants, UK) to 
300 mL RPMI liquid.  The solution was then autoclaved at 121°C for 15 min.  After 
cooling the autoclaved agar for 30 min in a 50-52°C water bath, it was poured into 
sterile petri dishes in a laminar flow cabinet.  The agar plates were left at room 
temperature to set and then kept in the cold room, at 4°C until needed.  RPMI was 




The initial determination of the susceptibility of representative Candida isolates from 
subjects to fluconazole was measured by agar diffusion with the Etest® (BioMérieux 
Inc., USA) system (Holmes et al., 2002).  C. albicans isolates from each patient were 
taken from the glycerol stocks and inoculated onto SDA plates.  The plates were 
incubated at 37°C for 48 h.  C. albicans colonies from the SDA plates were 
suspended in sterile saline (0.9% w/v NaCl) to give an optical density (OD) of 0.25 at 
a wavelength of 540 nm (OD540) using a spectrophotometer (Ultrospec 6300pro 
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Amersham Biosciences, NJ, USA).  This was in order to achieve a turbidity of 0.5 
McFarland units.  A sterile cotton swab was dipped into the yeast suspension, excess 
liquid squeezed out, and then the swab was spread evenly over an RPMI agar plate to 
make a lawn of C. albicans.  An Etest® strip was placed in the centre of the agar plate 
which was incubated at 37°C for 48 h.  
 
The plates were examined at 24 h and at 48 h.  The fluconazole diffused from the strip 
and inhibited the growth of the yeast when at high concentration, giving a clear zone 
of no growth around the strip (Figure 2.2).  The inhibition ellipse intersected the 
graduated strip at the MIC value (Holmes et al., 2002).  The size of the zone of 
growth inhibition around the strip gave a quantification of the susceptibility of the C. 
albicans isolate to fluconazole.  The plates were photographed in the PC2 MBL. 
 
 
Figure 2.2 Photograph of Etest® performed on one of the C. albicans isolates (a = the 




Broth microdilution MIC determination was performed using RPMI liquid medium in 
sterile 96-well flat-bottom microtitre plates (Nunc, Thermo Fisher Scientific Inc., 
Waltham, USA) to confirm the values obtained using the fluconazole Etest®.  The 
fluconazole used in this study was purchased as Diflucan from Pfizer (New York, 
USA) and kept as a stock solution (2 mg/mL) dissolved in sterile water. 
 
The diagram below shows the microtitre plate layout (Figure 2.3).  All the wells in 
rows A and G and columns 1 and 12 were filled with 200 µL RPMI to act as a 
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negative no-drug, no- inoculum control and to prevent desiccation of the inner 
microtitre plate wells during incubation. 
 
 
Figure 2.3 Liquid MIC microtitre plate layout  
 
All the inner wells were filled with 100 µL of RPMI except column number 11, which 
contained 200 µL fluconazole at the highest concentration (128 µg/mL).  The 
fluconazole in column 11 was diluted two-fold from right to left by taking 100 µL 
from column 11 and adding it to column 10, mixing and then taking 100 µL from 
column 10 and adding it to column 9 and so on until fluconazole was added to column 
number 3.  The contents of column 3 were mixed and then 100 µL removed and 
discarded. Column 2 contained only RPMI medium without fluconazole and was the 
positive cell growth (zero drug) control.  To each of the inner wells (i.e. not rows A or 
G nor columns 1 or 12) 100 µL of inoculum (prepared as described below) was added. 
 
C. albicans cells from glycerol stocks were subcultured onto SDA plates, and 
incubated at 35°C for 24 h.  Cells from single colonies were suspended in 1 mL RPMI 
growth medium to form a C. albicans pre-culture.  The pre-culture was incubated in a 
Multitron II shaker at 35°C with agitation at 200 rpm for 18 h.  The OD600 of the pre-
culture was measured and then the pre-culture was diluted 100-fold into 1 mL of fresh 
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RPMI solution and the culture was incubated at 35°C for 8 h. The OD600 of the 
culture was measured and it was diluted with fresh RPMI to get a standardised 
concentration of 4 x 103 cells/mL according to the CLSI (Clinical and Laboratory 
Standard Institute) recommended inoculum for C. albicans susceptibility assays.  This 
is to get the cell growth at exponential, pre-plateau phase at the time of testing in the 
MIC assay. 
 
This C. albicans cell suspension (100 µL of 4 x 103 cells/mL) was added to the inner 
wells of the microtitre plate in duplicate rows such that the plate tested 3 strains of C. 
albicans.  The plate was incubated at 35°C with agitation at 200 rpm for 48 h.  The 
amount of C. albicans growth in each well was measured by reading the OD600 using 
a Synergy 2 (Biotek Instruments Inc., Vermont, USA) microtitre plate reader at 24 h 
and at 48 h.  The MIC optical densities were recorded using Gen 5 Microtitre Data 
Collection Analysis software (Biotek Instruments Inc., Vermont, USA) and 
transferred into Microsoft Excel.  The minimum growth inhibitory concentration was 
defined as the minimum concentration of drug resulting in more than 80% growth 





Fluphenazine dihydrochloride was purchased from Sigma-Aldrich Corporation, St. 
Louis, Missouri, USA. The susceptibility of C. albicans to fluphenazine was 
measured by standard liquid MIC assays as described above (section 2.5.3.2) except 
the top final concentration of fluphenazine in the assay was 100 µg/mL.  Readings of 
the microtitre plate were undertaken at 24 h and at 48 h.  The results were interpreted 




Statistical analysis was undertaken using Microsoft Excel with StatPlus: mac LE 
(AnalystSoft.Inc, CA, USA).  The data obtained did not show normally distributed 
samples, thus the non-parametric statistical analysis comparing the mean 
concentration of C. albicans in the saliva rinses was done using Kruskal-Wallis test 
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whilst the individual comparison was done between the participants and healthy 





An agar diffusion synergism/antagonism assay was used to determine whether 
interactions between fluconazole and fluphenazine affected the growth of C. albicans.  
Amphotericin B (Sigma-Aldrich Corporation, St. Louis, Missouri, USA) was used as 
a negative control.  RPMI agar plates were inoculated with C. albicans cells as in the 
Etest® method (section 2.5.3.1).  The antifungal medications fluconazole (5 µL of 2 
mg/mL), fluphenazine (40 µL of 2 mg/mL), and amphotericin B (2 µL of 8 mg/mL) 
were put on sterile filter paper discs.  Thus the amounts of the antifungal medications 
placed on the discs were: fluconazole, 10 µg; fluphenazine, 80 µg; and amphotericin 




  Figure 2.4 Agar diffusion synergism/antagonism disc layout 
	
The zones of growth inhibition around the discs were recorded at 24 h and 
photographed using the camera in the PC2 MBL. Antagonism between the 
medications on two discs would result in yeast growth between the two discs. 
Synergism between the medications on two discs would result in increased growth 
inhibition between the two discs.	
	




A checkerboard liquid MIC assay was undertaken to measure the susceptibility of C. 
albicans strains to combinations of fluconazole and fluphenazine (Figure 2.5) and to 
get a quantitative measure of synergy or antagonism. 
 
The method was based on the normal liquid MIC assay (section 2.5.3.2).  Fresh C. 
albicans inoculum cell suspensions were prepared as described in section 2.5.3.2 but 
with a double concentration of 8 x 103 cells/mL.  The peripheral wells (rows A and G 
and columns 1 and 12) in a sterile 96-well, flat-bottom microtitre plate, termed the 
receiver plate, were filled with 200 µL RPMI to act as a negative no-drug, no-
inoculum control and to prevent desiccation of the inner microtitre plate wells during 
incubation.  A transfer plate was prepared by adding 100 µL RPMI in the inner wells 
of the microtitre plate except row B.  Then, 200 µL fluconazole (FLC) was added in 
the top row (row B, columns 2 to 11).  A two-fold dilution of the fluconazole was 
performed by by taking 100 µL from the wells in row B and mixing it with the RPMI 
in row C before 100 µL was taken from row C and added to row D.  This process was 
continued down to the bottom row (row E) where after mixing 100 µL solution was 
removed and discarded.  The top concentration of fluconazole was 64 µg/mL, this is 
four-times the required final concentration (16 µg/mL) as 50 µL was to be transferred 
from this plate to the receiver plate in a final volume of 200 µL.  The bottom row 
(row F) acted as a no-fluconazole control.   
 
The receiver plate was prepared by adding 100 µL RPMI to all inner wells apart from 
column 11, and putting 200 µL fluphenazine (FLUP) in column 11.  The top 
concentration of fluphenazine was 100 µg/mL.  A two-fold dilution of fluphenazine 
was carried out by transferring 100 µL fluphenazine from column 11 from right to the 
left, as described for fluconazole in section 2.5.3.2 (Figure 2.3).  Column 2 acted as a 
no-fluphenazine control.  Then, 50 µL fluconazole from each inner well of the 
transfer plate was added to the corresponding well on the receiver plate.  The final top 
concentration of fluconazole in the plate is 16 µg/mL.  Finally, 50 µL inoculum cell 
suspension was added to all the inner wells.  The microtitre plate was incubated at 
35°C with agitation at 200 rpm for 48 h.  The OD600 of the microtitre plate wells were 
recorded at 24 h and at 48 h. 




Figure 2.5 Checkerboard MIC microtitre plate layout  
 
Antagonism between the two medications in the checkerboard MIC would result in 
more yeast growth for combinations of the medications than expected. Synergism 
between the two medications in the checkerboard MIC would result in less yeast 















Recruiting the required number of participants for this study was a challenging task.  
When dealing with individuals with mental health issues, their co-operation is often 
unpredictable.  Some of the patients agreed to participate when invited, but suddenly 
changed their minds when they were booked for the actual appointment.  Finally, nine 
participants were recruited in this study.  Their medical history was recorded, 
including the regular medications they were taking during this study.  Some 
participants needed to have some assistance understanding instructions and when 
answering the questions.  A general data for study participants can be viewed in the 
Table 3.1.   
 
There were two matched control groups, nine participants with xerostomia taking no 
antipsychotic medication and nine healthy individuals.  These patients were not seen 
as part of the current study, but their information was gathered from a related project 
performed by Leanne Xiao Li Hou for her Doctor of Clinical Dentistry degree titled 
“Oral yeast carriage and salivary protein profiles in xerostomia subjects and in age- 
and gender-matched controls”.   
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Medical conditions Antipsychotic 
medications 





P1 69 M Psychiatric problem, 
hypertension 
 
Lithium, risperidone Felodipine, metoprolol Y Y 
P2 51 M Schizophrenia Quetiapine, flupentixol 
(depiclor) injection 
 
Nil N N 
P3 47 M Schizophrenia, thyroid 
problems 





P4 50 M Schizophrenia Olanzapine Nil 
 
Y N 
P5 54 M Schizophrenia Risperidone Nil 
 
N N 




P7 46 M Schizophrenia Clozapine, lithium, 
haloperidol 
 
Sodium valproate Y Y 
P8 64 F Psychiatric problem, 
hypertension 












The majority of the participants in the study group were males (7 of 9, 78%).  Their 
age ranged from 47 to 64 years with most (56%) belonging to the age group of 50 to 
59 years old.  Table 3.2 summarises the age group and gender of the participants.  The 
oldest participant in this study was aged 69 and the youngest was aged 46 years at the 
time of recruitment.  The ethnicity of all the participants was European.    
 
Sex Age group (years)/number of participants Total (n=9) 













Table 3.2 Age and gender of participants 
 
The participants were age-matched as closely as possible with individuals from the 
control groups (Figure 3.1).  The age difference between the study participants and 
the control groups ranged from 0 to 12 years.  This was accepted to avoid large age 
differences between all the groups.  However, the gender for the study participants 
and the control groups could not be matched because the majority of the control 
participants were female (90%).  Xerostomia is more commonly reported in women, 
with an average of 8% higher prevalence than men (Orellana et al., 2006). 
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Figure 3.1 Individual age comparisons between participants with xerostomia not 
taking antipsychotic medications, participants taking antipsychotic medications and 





The dental files of the participants were obtained from the records office of the 
Faculty of Dentistry, University of Otago.  Their updated medical conditions and list 
of current medications were recorded.  Participants or carers were advised to bring 
along an updated list of medications when they came for data collection.  Table 3.3 
summarises the medical conditions of the recruited participants.  Most of the 
participants suffered from schizophrenia (55.6%).  Some participants suffered from 
other psychiatric problems that were not specified in their dental files.  Two 
participants reported hypertension along with psychiatric problems.  One participant 
suffered from depression, anxiety and eating disorders (bulimia and anorexia).  Of the 
seven male participants, five (71.4%) had schizophrenia, whilst the other two had 
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Medical conditions Number of participants 
(n=9) 
Schizophrenia 4 
Schizophrenia and hyperthyroidism 1 
Depression, anxiety, bulimia and anorexia 1 
Psychiatric problem (not specified) 1 
Psychiatric problem (not specified) and hypertension 2 




Most participants were on a combination of medications.  It was very uncommon for 
participants to be taking antipsychotic medications exclusively as their regular 
medications.  Only three (33%) of the participants were exclusively taking 
antipsychotic medications, namely quetiapine, olanzapine, risperidone and flupentixol 
(depixol) injection as their regular medications.  One (11%) of the participants was on 
a combined therapy of quetiapine and flupentixol injection.  Another participant was 
on a combined therapy of clozapine, lithium, haloperidol and sodium valproate 
(epilim).  Sodium valproate is an anticonvulsant, frequently used as an adjunct for the 
treatment of psychiatric disorders as a mood stabiliser.  Other anticonvulsants that 
were prescribed to the participants were lamotrigine, clonazepam and carbamazepine 
(tegretol).  Three (33%) of the participants had a combined therapy of typical 
antipsychotic medications and atypical antipsychotic medications.  Figure 3.2 displays 








Figure 3.2 Antipsychotic medications taken by each participant (typical 
antipsychotics – haloperidol and flupentixol, atypical antipsychotics – buspirone, 
lamotrigine, olanzapine, clozapine, quetiapine, risperidone, lithium)  
	
 
Two participants (22%) were on antipsychotic therapy combined with beta-blockers 
(metoprolol and propranolol) and statins (simvastatin) for their hypertension.  One 
participant was also prescribed a calcium-channel blocker (felodipine) for the 
treatment of hypertension.  Two (22.2%) of the participants were taking citalopram, a 
selective serotonin reuptake inhibitor antidepressant, along with their antipsychotic 
medications.  An anticholinergic agent, benztropine was also added into the 
medications list for another two (22%) of the participants to reduce the side effects of 
antipsychotic medications.  Hypnotic agents such as zopiclone were prescribed for 
two (22%) of the participants.  One of the participants was taking carbimazole for the 
treatment of his thyroid problems.  Other medications included docusate (laxative), 
metoclopramide (anti-emetic) and omeprazole (proton-pump inhibitor).  
 
A large number of medications, including antipsychotic medications, may cause dry 
mouth as a side effect.  Several participants in this study were found to be taking 
xerogenic medications as their regular medications.  Table 3.4 shows the group of 
xerogenic medications and the number of participants taking those medications. 
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Drug name Drug group Number of participants 
(percentage) 
Metoprolol, propranolol Beta-blocker 2 (22) 
Citalopram Selective serotonin 
reuptake inhibitor (SSRI) 
1 (11) 
Zopiclone Hypnotic 2 (22) 
Omeprazole Proton-pump inhibitor 1 (11) 
Table 3.4 Other medications associated with dry mouth being taken by participants (n 
= 9)  
 
The medical conditions of the xerostomia control group included cardiovascular 
diseases and autoimmune connective tissue diseases.  Participants with self-reported 
Sjogren’s syndrome were not included in the control group for this study.  Some of 
the healthy control group from the Hou study were taking medications including 
tricyclic antidepressant, antihypertensive, anticholinergic, medication for arthritis, 
cholesterol lowering medication, cardio medication, diuretics and antihistamines.  
However, the medications being taken by particular control subjects were not 
specified (Hou, 2012), thus the medication status of the matched control group for this 




The current smoking status of the participants was recorded after they were recruited.  
Three (33%) of the participants were current smokers and the rest were non-smokers.  
No ex-smokers or quitters were identified during the data collection.  All three 




The denture status of the participants was also recorded during recruitment into this 
study.  The majority of the participants (67%) were non-denture wearers.  Two of the 
participants had complete upper and lower dentures and one of them had an upper 
partial denture.  Two of the denture wearers were male participants (aged 46 and 69 
years old) while the female participant was 64 years old.  





The Xerostomia Inventory (XI) was used in this study to evaluate the participants’ 
subjective feeling of dry mouth.  The highest total XI score obtained from participants 
in this study was 32.  This was obtained from a 52-year old female participant (P6).  
This participant was on multiple medications including flupentixol, quetiapine, 
benztropine, calcium, docusate, multivitamins and metoclopramide.  The lowest total 
score was 14, provided by two participants (P2 and P4), both male, belonged to the 
age group 50-59.  One of them (P2) was on quetiapine and flupentixol injection while 
the other one (P4) was on olanzapine alone.  Both were non-denture wearers, but one 
of them was a smoker (P4).  Table 3.5 summarises the answering pattern of 
participants based on the four answering options (“never”, “occasionally”, 
“frequently” and “always”).  Numbers in the answering options column indicate the 
number of participants that had chosen that answer.  The highest number of 
participants choosing the same answer option was six (67%), where they occasionally 
sip liquids to aid in swallowing food and felt their lips were dry.  This shows that 
most participants respond to the feeling of dry mouth by sipping liquids to help them 
swallow food.  Interestingly, all the participants felt their mouth were dry with 
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Items in XI Never Occasionally Frequently Always 
How often does your mouth feel dry?     
My mouth feels dry 0 3 5 1 
I have difficulty in eating dry food 4 3 1 1 
I get up at night to drink 4 4 1 0 
My mouth feels dry when eating a meal 4 4 0 1 
I sip liquids to aid in swallowing food 2 6 1 0 
I suck sweets or cough lollies  
to relieve dry mouth 
5 2 0 2 
I have difficulties in swallowing certain 
foods 
5 4 0 0 
The skin of my face feels dry 5 1 3 0 
My eyes feel dry 5 2 1 1 
My lips feel dry 2 6 0 1 
The inside of my nose feels dry 4 3 1 1 
Table 3.5 Number of participants with their answer options (n=9) 
 
Five participants (56%) who “frequently” found that their mouth was dry were on a 
combination of medications.  One participant (P6) always felt that her eyes, lips and 
the inside of her nose were dry.  This participant scored the highest total in XI score 
in this study.  About half of the participants never sucked sweets or cough lollies to 
relieve their dry mouth, had difficulty in swallowing certain foods or felt the skin of 
their face and eyes were dry.  Two of the participants (P1 and P9) answered “always” 
sucking sweets or cough lollies to relieve dry mouth, which might contribute to teeth 
loss (one of them wore complete upper and lower dentures).  This participant (P1) 
was also a smoker, whose medications were lithium, risperidone, simvastatin and 
metoprolol.  Figure 3.3 illustrates the mean XI score based on the frequency of dry 
mouth for the main question “How often does your mouth feel dry?” 
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All participants had a clinical examination by the candidate after recruitment into this 
study.  A standard sterile mouth mirror and dental operating light were used in every 





Evidence of dry mouth such as lack of saliva pooling, depapillated tongue, mouth 
mirror sticking to the buccal mucosa and frothy saliva was recorded for each 
participant.  Figure 3.4 shows an example of lack of saliva pooling from one of the 
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Figure 3.4 Lack of saliva pooling in one of the participants 
 
Figure 3.5 summarises the number of participants with clinical evidence of dry 
mouth.  Only two (22%) of the participants (P2 and P5) had no clinical evidence of 
dry mouth.  Almost all (78%) of the participants showed lack of saliva pooling during 
the clinical examination.  Five (56%) had a combination of two or more signs of dry 




Figure 3.5 Number of participants (n = 9) with clinical evidence of dry mouth (FS – 
frothy saliva, DT – depapillated tongue, SP – lack of saliva pooling, MM – mouth 
mirror sticks to the buccal mucosa, COMB – combination of 2 or more evidence and 
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One of the two participants who had no evidence of dry mouth was taking quetiapine 
and flupentixol injection (P2) and the other one was taking risperidone only (P5).  





Only one (11%) of the participants had clinical evidence of oral candidal infection.  
This was confirmed by wiping off whitish plaques on the participant’s hard palate and 
right buccal mucosa using a piece of sterile gauze, leaving a raw area on the mucosa. 
The participant (P1) was a 69-year old man wearing complete upper and lower 
dentures constantly without removing them at night.  The other participants did not 
show any signs of oral Candida infection during the examination.  




















Lack of saliva 
pooling 
Mouth mirror sticks 
to the buccal mucosa 
None 
P1 Lithium, risperidone Felodipine, 
metoprolol 
22 ✓ ✓ ✓   
P2 Quetiapine, 
flupentixol injection 
Nil 14     ✓ 




26  ✓ ✓   
P4 Olanzapine Nil 14   ✓   







32  ✓ ✓   
P7 Clozapine, lithium, 
haloperidol 
Sodium valproate 15 ✓  ✓   











26  ✓ ✓ ✓  
Table 3.6 Individuals’ Xerostomia Inventory (XI) scores and their clinical presentations.




Three (33%) of the participants showed PAS-positive Candida hyphae on all the 
smears that were taken as part of this study.  One participant (P5) had negative results 
on both buccal mucosal smears but had occasional PAS positive Candida hyphae on 
the tongue smear.  One participant (P9) showed positive PAS staining of Candida 
hyphae only on the tongue smear but not the smears from the right and left buccal 
mucosa.  Four (44%) had negative PAS staining of the candidal hyphae.  Two (P1 and 
P7) of the four participants diagnosed with oral candidosis by the Medlab Dental 
laboratory had upper dentures, either complete or partial.  Figure 3.7 illustrates the 
PAS staining of Candida hyphae results for each participant.  Participant P9 was not 
diagnosed with oral candidosis due to the absence of Candida hyphae in the smears.  
Participant P1 underwent a palatal smear due to the clinical evidence of oral Candida 





Figure 3.6 Example of positive PAS staining of Candida hyphae at 10x magnification 
(left) and 40x magnification (right).   
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This part of the investigation identified the sociodemographic characteristics of the 
participants in the present study and their medical background.  The link between 
antipsychotic drug intake and the presence of dry mouth could be established 
especially when most of the participants (78%) presented with dry mouth.  However, 
the condition of the dry mouth symptoms they experienced were not severe based on 
the XI scores they obtained.  Most participants (6 of 9) felt that their mouth was dry, 
but the condition was not too severe for them to notice or to induce them to modify 
their behaviour towards dry mouth such as drinking water to aid in swallowing.  The 
presence of oral candidosis in four of the participants could also be associated with 
the antipsychotic drug intake, although not directly because only one of these 
participants was exclusively taking an antipsychotic drug (risperidone).  The other 
participants were on a combination of medications for their underlying medical 
condition.  

















Candida species are normally present in the oral cavity (Cannon and Chaffin, 1999) 
with Candida albicans being the most prevalent species (Cannon et al., 1995).  It has 
been found that a decrease in salivary flow rate correlates with an increase in the 
number of Candida cells in the oral cavity (Torres et al., 2002).  It is also known that 
xerostomia is a side effect of many antipsychotic medications.  This part of the study 
was specifically designed to determine not only the species that are present in the oral 
cavity of individuals taking antipsychotic medications, but also the level of 
colonisation by Candida species and their susceptibility to antifungal medications.  
The level of colonisation of the oral mucosa with Candida in people taking 
antipsychotic medications will be compared to that in xerostomic patients and their 
healthy controls not prescribed with antipsychotics.  These individuals may be taking 
medications with xerostomic potential or have systemic conditions resulting in 
xerostomia.  Furthermore, the fluconazole susceptibility of the C. albicans strains 
isolated from the patients taking antipsychotic medications will be measured and the 
effect of fluphenazine (one of the older, highly potent first-generation piperazine class 
of phenothiazine antipsychotic medications, in the same class with perphenazine and 
prochlorperazine) on this susceptibility will be determined.  In vitro studies have 
shown that fluphenazine is capable of inducing expression of ATP-binding cassette 
(ABC) efflux pumps, such as Cdr1p, in C. albicans cells (de Micheli et al., 2002; 
Coste et al., 2004; Manoharlal et al., 2011).  This pump reduces the intracellular azole 
concentration in C. albicans cells grown in the presence of azoles resulting in 
resistance to azoles' growth inhibitory effect.  ABC efflux pump activity plays a major 
role in clinical azole antifungal resistance (Cannon et al., 2009).   
  




The microbiological analysis of participants’ samples was carried out as described in 
Section 2.5.2 in the “Materials and Methods” chapter.  Colonies growing on the 
CHROMagar™ Candida plates were presumptively identified, counted, and recorded 
as colony-forming units per mL saliva rinse (CFU/mL).  Table 4.1 compares the 
colonisation levels of the different Candida species identified.  In the present study, 
four different colony types were identified, and most participants (6 of 9) were 
colonised with C. albicans.  The table shows that the lowest concentration of C. 
albicans was 9 CFU/mL and the highest was 3979 CFU/mL.  The highest mean level 
of colonisation for all participants was by C. albicans (517 CFU/mL) and the lowest 























6 9 - 3979 776 517 
C. tropicalis 
(purple/blue) 
1 0 - 192 192 21 
C. krusei 
(pink) 
2 1 - 596 299 261 
Unidentified 
(white)  
1 0 - 3200 3200 356 
Table 4.1 Presence of Candida species in participants’ saliva rinses 
 
The colonisation of individual participants is shown in Figure 4.1.  Seven out of nine 
participants (77.8%) were yeast-positive and for two participants no yeasts were 
detected in their saliva rinse samples.  Samples from four participants contained a 
single colony type, two contained two-colony types and one contained three-colony 
types.  Colony type (presumptive species) details are summarised in the Table 4.1.  
Six out of seven positive saliva rinse samples (85.7%) had colonies presumptively 
identified as C. albicans and three participants (33.3% of all participants; 43% of 
yeast-positive participants) contained only C. albicans (green colonies) in their saliva 
rinse.  The highest number of colony types was obtained from participant P9, where 
three types of colonies were identified including C. albicans, C. krusei (pink colonies) 
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and other species (white colonies).  Three participants had C. krusei in their saliva 
rinse samples, with participant P9 having the highest concentration.  Only one 
participant (P6) grew C. tropicalis from the saliva rinse.  This participant also had the 
highest C. albicans CFU/mL when compared to the other participants.  
 
 
Figure 4.1 Colonisation of individual participants by different yeast species (CFU/mL 
saliva rinse) 
 
Table 4.2 compares the oral candidosis diagnosis from the cytological study (Section 
3.9) with the concentration of yeast in the saliva rinse.  Four participants had a 
diagnosis of oral candidosis and all four were colonised with yeasts.  Participant P6 
presented with the highest colonisation by Candida species and was a 52 year-old 
female on multiple medications including flupentixol, quetiapine, benztropine, 
docusate, metoclopramide, calcium and multivitamin.  All three of her oral smears 
gave positive PAS staining resulting in a clinical diagnosis of oral candidosis.  
Interestingly, participant P9 who had the second highest concentration of C. albicans 
(561 CFU/mL) and C. krusei (1755 CFU/mL) in his saliva rinse, did not have PAS 
positive smears except from the tongue.   He had not been diagnosed with oral 
candidosis.  The risk of oral candidosis has been reported to be higher with denture or 
prosthesis wearing, hyposalivation or dry mouth and in elderly individuals (Campisi 
et al., 2007).   The colonisation of participant P1 is in accord with this observation; P1 
P1 P2 P3 P4 P5 P6 P7 P8 P9 
Green 48 0 0 10 9 3979 46 0 561 
Purple/blue 0 0 0 0 0 192 0 0 0 
Pink 0 0 0 0 0 0 596 1 1755 
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was a 69 year-old man, wearing complete upper and lower dentures with clinical 
evidence of dry mouth and oral candidosis.  Three of the four participants with a 
clinical diagnosis of oral candidosis presented with the clinical indication of dry 
mouth.  Participants P2 and P6 were taking flupentixol, a typical antipsychotic drug in 
the thioxanthene class, which is closely related chemically to the phenothiazine class 
of antipsychotics which includes fluphenazine.  Interestingly, participant P6 had the 














P1 Yes 48 Yes Yes 
P2 No 0 No No 
P3 No 0 No Yes 
P4 No 10 No Yes 
P5 Yes 9 No No 
P6 Yes 4171 No Yes 
P7 Yes 642 Yes Yes 
P8 No 1 Yes Yes 
P9 No 2316 No Yes 
Table 4.2 Comparison of clinical oral candidosis diagnosis with concentration of 
yeasts in saliva rinses.  Results highlighted in blue are for participants with a clinical 
diagnosis of oral candidosis. 
 
 
The findings from the present study were compared to those obtained in a previous 
study for two other groups: individuals with xerostomia (n = 9) and age- and gender-
matched controls without xerostomia and not on antipsychotic medications (n = 9) 
(Hou, 2012).  Control participants from the Hou study were age-matched with the 
current study participants, but gender-matching was not possible because the Hou 
study had mostly female participants (90%).  The yeast species present in the saliva 
rinses from healthy controls were C. albicans (1 of 9) and C. glabrata (1 of 9).  The 
mean concentration of C. albicans in participants’ saliva rinses from the present study 
was slightly less than that for the xerostomia participants in the Hou study not taking 
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antipsychotic medications (Figure 4.2).  The data obtained showed a skewed 
distribution, thus the statistical analysis comparing the mean concentration of C. 
albicans in the saliva rinses was done using the Kruskal-Wallis test.  The test revealed 
a statistically significant difference (H = 10.38, df = 2, p<0.05) between the three 
groups.  An individual comparison was done between the participants and healthy 
control using the Mann-Whitney U test that indicated a statistically significant 
difference (p<0.05).  However, a Mann-Whitney U test between the participants and 
xerostomia subjects did not show statistical significance (p>0.05).  This is probably 
due to the similarity of the conditions between the two groups, which both displayed 




Figure 4.2 Mean concentrations (CFU/mL) of C. albicans in saliva rinse samples from 

















L	 Study participants (SD: 
1310.8) 
Xerostomia (SD: 680.2)* 
Control (SD: 7.7)* 
*Data from Hou, 2012 






Glycerol stocks of yeast isolates were prepared from four colonies for each of the 
saliva rinse samples from yeast-positive participants.  When a saliva rinse contains 
two species of Candida, two colonies from each species were inoculated.  Six 
participants were C. albicans positive and two isolates from each of these samples 
(twelve isolates) were analysed for antifungal susceptibility.  They were labeled W1a, 
W1b, W4a, W4b, through to W9a and W9b based on the origin of the isolates (the 
number refers to the C. albicans-positive participant).   
 
The agar diffusion susceptibility assay using the Etest® method was described in 
Section 2.5.3.1.  This method was used for the preliminary determination of the 
susceptibility of C. albicans isolates obtained in this study to fluconazole.  
Application of the Etest® strips containing fluconazole resulted in elliptical zones of 
growth inhibition that crossed the graduated strip, and the MIC was recorded as the 
concentration value at which the ellipse crossed the scale on the strip (Figure 4.3).  
This figure shows representative images of two types of growth pattern.  For some 
isolates (e.g. W7b) a clear elliptical inhibition zone was observed (Figure 4.3; b and 
d) in this example giving an MIC of 0.125 µg/mL.  For other isolates (e.g. W1a) the 
inner zone showed partial inhibition of growth, known as trailing growth (Lee et al., 
2004), which, however, is not reflected in clinical resistance of strains showing this 
effect (Pfaller et al., 1998).  In such examples, the MIC was taken as the point at 
which the inner zone of lesser growth crossed the strip (0.38 µg/mL for isolate W1a) 













Figure 4.3. Representative Etest® results for two apparently fluconazole-sensitive 
isolates.  Examples shown are for the isolates W1a (a and c); and W7a (b and d).  In 
the images (c) and (d), the green lines trace the elliptical zones of inhibition to 
indicate the MIC values (0.38 µg/mL for W1a; 0.125 µg/mL for W7a). 
 
 
The Etest® results for the twelve C. albicans isolates obtained from saliva rinse 
samples of the six C. albicans-positive participants are given in the Table 4.3.  A low 
MIC value indicates high susceptibility to fluconazole, for example isolate W1b was 
highly susceptible to fluconazole because it had the lowest MIC value (0.064 µg/mL) 
compared to the other isolates.  In contrast, the isolates W4a, W4b, W6a, and W6b 
showed apparently uniform growth over the whole plate containing the Etest® strip, 
giving apparent MIC values greater than 256 µg/mL (Figure 4.4 shows the Etest® 
plate results for isolates W4a and W4b).  Therefore, based on the use of this method, 
these isolates were apparently resistant to fluconazole.  The interpretive susceptibility 
breakpoints for fluconazole and Candida spp. are considered to be as follows: 
sensitive: MIC ≤ 8 µg/mL; resistant: MIC ≥ 64 µg/mL (Pfaller et al., 2006).   
Interestingly, two pairs of the apparently resistant isolates were from the same 
participants (W4a and W4b; W6a and W6b) and showed similar patterns of growth in 
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the Etest®. In conclusion, seven (58.33%) of the twelve C. albicans isolates tested 
were found to be susceptible to fluconazole using the Etest® method. 
 
 
Figure 4.4 Etest® plates for two apparently fluconazole-resistant isolates (W4a and 




Participant ID C. albicans isolate Apparent MIC  
(µg/mL)  
P1 W1a 0.38 
W1b 0.064 
P4 W4a >256 
W4b >256 
P5 W5a 0.5 
W5b 0.5 
P6 W6a >256 
W6b >256 
P7 W7a 0.125 
W7b 0.19 
P9 W9a >256 
W9b 0.125 
Table 4.3 Apparent fluconazole susceptibilities of C. albicans isolates determined by 





The liquid microdilution method for measuring the susceptibility of C. albicans to 
fluconazole was described in Section 2.5.3.2.  The minimum inhibitory concentration 
(MIC80) was the lowest concentration of fluconazole that resulted in at least 80% 
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growth inhibition of C. albicans.   The readings were taken at 24 h and 48 h, but 
values at 24 h were more reliable.  If the amount of growth after 24 h was plotted as a 
proportion of growth in the no-drug control versus the fluconazole concentration, it 




Figure 4.5 Growth inhibition of C. albicans by fluconazole (t = 24 h). Typical growth 
inhibition curves for four C. albicans isolates (W4a, W4b, W7a, and W9a) from 
which MIC values were calculated. 
 
 
The growth inhibition pattern for fluconazole typically shows ‘trailing growth’ 
whereby a certain amount of growth persists even at high fluconazole concentrations 
(eg isolates W4b and W7a, Figure 4.5).  This is why a cut-off of 80% growth 
inhibition (rather than 100% growth inhibition) was used to measure fluconazole MIC 
values. Only isolate W9a demonstrated total growth inhibition - at a fluconazole 
concentration of 0.5 µg/mL.  The liquid MIC values for all C. albicans isolates were 
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Figure 4.6 Fluconazole MIC values (µg/mL) after 24 h for C. albicans isolates  
 
 
A majority (66.7%) of the isolates had a fluconazole MIC80 value of 0.5 µg/mL 
(Figure 4.6).  Three of the isolates had a fluconazole MIC80 value of 1 µg/mL.  One of 
the isolates had a higher fluconazole MIC80 value of 2 µg/mL.  The breakpoint for 
fluconazole resistance as determined by liquid MIC is 64 µg/mL (Pfaller et al., 2006; 





The standard liquid MIC technique (Section 2.5.3.3) was also used to determine the 
fluphenazine MIC values for the C. albicans isolates.  The results were recorded at 24 
h and 48 h - the values at 48 h were found to be more reliable.  Figure 4.7 shows an 
example of the growth pattern for the isolate W9a after 48 h.  The fluphenazine MIC 
value for this isolate was 100 µg/mL.  Unlike fluconazole, fluphenazine achieved a 
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Figure 4.7 Growth inhibition of C. albicans isolate W9a by fluphenazine. 
 
The fluphenazine MIC values for all the C. albicans isolates used in this study, taken 
at 48 h are shown in Figure 4.8.  Fluphenazine does not have a strong antifungal 
activity.  The majority of the isolates (75%) had the same fluphenazine MIC value of 
50 µg/mL.  Three of the isolates had a higher fluphenazine MIC value (100 µg/mL).  
The MIC value of 100 µg/mL was used as a reference for fluphenazine for conducting 
the checkerboard susceptibility experiments described in Section 2.5.3.6.  
 
 


















































The technique for measuring drug synergy/antagonism using the disc diffusion assay 
is described in Section 2.5.3.5.  Figure 4.9 (showing plates inoculated with isolates 
W6a and W9b) displays two examples of the disc diffusion assay results obtained.  
The zones of growth inhibition around the fluconazole disc are flattened opposite the 
fluphenazine discs, and yeast growth is observed between the two discs, indicating an 
antagonistic interaction between fluconazole and fluphenazine.  Similar results were 
observed for five other isolates, and no example of synergy (coalescing zones of 
inhibition) was observed for any isolate.  Note that the zones of growth inhibition 
around the fluphenazine discs are small, because this compound has little antifungal 
activity, yet fluphenazine is clearly diffusing some distance from the fluphenazine 
discs in order to reduce the effect of fluconazole on growth of the yeast.   For some 
isolates, antagonism was also observed between fluconazole and amphotericin B (see 




Figure 4.9 Disc diffusion analysis of drug synergy/antagonism.  Isolate W6a (left), 











The checkerboard liquid MIC susceptibility assay method was carried out as 
described in Section 2.5.3.6.  This test was undertaken to investigate in more detail 
whether fluphenazine induces fluconazole resistance in C. albicans because 
fluphenazine is known to cause upregulation of drug efflux pump genes CDR1 and 
CDR2 mRNA expression by up to 500 fold (de Micheli et al., 2002; Zhu et al., 2014).  
An increase in fluconazole resistance in the presence of fluphenazine would be seen 
as antagonism in a checkerboard assay, confirming the disk assay results described 
above (Section 4.3.4).   The results presented use MIC absorbance readings taken 
after 24 h of incubation.  Figures 4.10 to 4.12 show typical checkerboard results - for 
the isolates W1a, W5b and W9b.  The columns at the left of each graph show the 
growth inhibition by fluconazole in the absence of fluphenazine; the top rows show 








































Chapter 4: Microbiological Analysis 
	 96	
 




Figure 4.12 Checkerboard result for isolate W9b.   
 
 
The data show that growth of each of the isolates was substantially reduced (>80%) in 
the presence of 1 µg/mL fluconazole alone (the lowest concentration of fluconazole 
tested), therefore the fluconazole MIC80 values for each of these three isolates is <1.0 
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reduced in the presence of fluphenazine at concentrations between 0.35 – 3.125 
µg/mL, with an increase in the fluconazole MIC80 values to between 4.0 µg/mL 
(isolates W1a and W9b) and 8.0 µg/mL (isolate W5b).  Thus the fluphenazine was 
antagonising the antifungal effect of fluconazole.  In contrast, the MICs of 
fluphenazine for these isolates were unaffected by the presence of fluconazole.  Under 
these conditions (24 h growth), the fluphenazine MICs in the presence and absence of 
fluconazole were equal at 3.125 µg/ml.; a lower value than that observed at 48h 
(Figure 4.8), possibly reflecting incomplete growth of the cultures at the time of 
observation.  However, the data demonstrate that in contrast to the effect of 
fluphenazine on the fluconazole MIC, fluconazole was not having an effect on the 
cells’ susceptibilities to fluphenazine. 
 
The interactions between fluconazole and fluphenazine were assessed by calculating 
the fractional inhibitory concentrations (FICs) for each drug, that were then combined 
to give the fractional inhibitory concentration index (FICI) for these drug 
combinations.  FICs and FICIs were calculated as follows: 
 
 
The FICI values can be used to classify the interactions between two medications as 
being either synergistic or antagonistic.  An FICI value of < 0.5 indicates a synergistic 
interaction, while an FICI value of > 4.0 indicates an antagonistic interaction (Odds, 
2003).  A value between 0.5 and 4.0 indicates no significant interaction between the 
two medications. 
 
Table 4.5 shows the FIC and FICI values for the twelve C. albicans isolates studied 
(two from each of the participants who had C. albicans in their saliva samples).  Five 
isolates (W1a, 5a, 5b, 7b and 9b) had FICIs of >4.0 indicating significant antagonism 
FICI = FIC of fluconazole + FIC of fluphenazine 
 
FIC of fluconazole = MIC value of fluconazole + fluphenazine 
       MIC value of fluconazole only 
 
FIC of fluphenazine = MIC value of fluphenazine + fluconazole 
       MIC value of fluphenazine only 
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(Odds 2003).  Other FICI values were between 1.0 and 3.0 suggesting a trend towards 




FLC MIC80 (µg/mL) FLUP MIC (µg/mL)  
FICI Alone Combined* FIC Alone Combined* FIC 
W1a <1.0 4.0 (1.5) >4.0 3.125 3.125 (1.0) 1.0 5.0 
W1b 2.0 4.0 (0.75) 2.0 >100.0 3.12 (2.0) <0.03 2.0 
W4a 8.0 8.0 (0.37) 1.0 >100.0 6.25 (1.0) <0.06 1.0 
W4b 2.0 4.0 (0.37) 2.0 12.5 12.5 (1.0) 1.0 3.0 
W5a <1.0 4.0 (0.37) >4.0 6.3 6.25 (1.0) 1.0 5.0 
W5b <1.0 8.0 (0.75) >8.0 6.3 6.25 (1.0) 1.0 9.0 
W6a <1.0 2.0 (0.37) >2.0 6.3 3.12 (1.0) 0.5 2.5 
W6b 2.0 2.0 (0.37) 1.0 >100.0 3.12 (1.0) <0.03 1.0 
W7a 2.0 4.0 (0.75) 2.0 3.12 3.12 (1.0) 1.0 3.0 
W7b <1.0 8.0 (0.37) >8.0 3.12 3.12 (1.0) 1.0 9.0 
W9a <1.0 2.0 (0.37) >2.0 12.5 12.5 (1.0) 1.0 3.0 
W9b <1.0 4.0 (0.75) >4.0 3.12 3.12 (1.0) 1.0 5.0 
 
Table 4.5 Fractional inhibitory concentration index (FICI) value for twelve C. 
albicans isolates.  Results highlighted in green show significant antagonistic 
interactions. 
* The combined MIC was measured in the presence of the other compound (FLUP or 
FLC) at the concentration (µg /ml) indicated in parentheses. 
 
  




The microbiological analysis of saliva samples in this study found a significantly 
higher number of participants were colonised with Candida spp. (7 of 9) when 
compared to an age-matched group of healthy individuals (2 of 9).  The numbers of 
yeast detected per participant was also significantly higher than for the control group 
(Figure 4.1).  Although a direct correlation between antipsychotic medications intake 
and the level of colonisation by Candida spp. could not be established, increased 
colonisation may have been because antipsychotic medications are known to have a 
side effect of reduced saliva production (Zelickson and Rogers, 1986; Scully, 2003; 
Haddad and Sharma, 2007).  Seven of nine participants in the current study presented 
with symptoms of dry mouth (Table 4.2).  This is in agreement with previous studies 
demonstrating a correlation between high levels of Candida colonisation and 
xerostomia (Navazesh et al., 1995; Torres et al., 2002; Torres et al., 2003; Hou, 
2012).  Clozapine is thought to induce hypersalivation (Haddad and Sharma, 2007).  
The present study found that the participants who were taking clozapine presented 
with dry mouth (P3 and P7).  However, they were also on other medications that may 
contribute to dry mouth.  The most frequently identified Candida species 
(presumptive identification by colony colour) in the present study was C. albicans 
(Table 4.1); although three other colony types were detected which were 
presumptively identified as C. tropicalis (purple/blue), C. krusei (pink) and an 
unknown species (white).  It has been reported that some Candida glabrata isolates 
produce white colonies on CHROMagar™ Candida (Bishop et al., 2008). 
Confirmation of the species of the white colony would require nutritional utilisation 
tests (ability to grow on various carbon and nitrogen sources) or deoxyribonucleic 
acid (DNA) sequence analysis.  The observation that C. albicans was the most 
common species detected is in agreement with other reports regarding oral Candida 
species (Coronado-Castellote and Jiménez-Soriano, 2013).  Although Candida 
colonisation was found in 7 of 9 participants, the prevalence of a clinical diagnosis of 
oral candidosis in the participants was lower (4 of 9); however this might be expected 
as Candida species are commensal organisms and therefore detection of C. albicans 
does not necessarily indicate disease (Mayer et al., 2013).    
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In vitro measurement of the susceptibility of yeasts to fluconazole can be undertaken 
following the standardised CLSI (formerly National Committee for Clinical 
Laboratory Standards (NCCLS)) guidelines using the spectrophotometric MIC broth 
microdilution procedure, agar based methods including disc diffusion susceptibility 
assay, and using the commercially available Etest® strips (Pfaller et al., 1998; 
Holmes et al., 2002; Pfaller et al., 2006).  However, getting a reliable measure of 
susceptibility with the Etest® was difficult due to the presence of a large number of 
microcolonies within the zone of inhibitions.  For example, when the Etest® was used 
to measure the C. albicans isolates’ susceptibilities to fluconazole, five (W4a, W4b, 
W6a, W6b and W9a) (Table 4.3) were apparently resistant to fluconazole.  It has been 
reported that the Etest® can be unreliable, particularly when a trailing pattern of 
growth is present (Alp et al., 2010).  In contrast, when a liquid microtitre assay was 
used, based on the "gold standard" CLSI methodology (Rex et al., 2008), all twelve 
isolates were susceptible. 	
 
The effect of antipsychotic medications on fluconazole susceptibility has not been 
well studied.  However, as it was discovered in this study that participants on 
antipsychotic medication had increased prevalence of Candida colonisation it was 
important to test the effects of antipsychotic medications on C. albicans fluconazole 
susceptibility.  Importantly, this study confirmed the earlier molecular studies on 
efflux pump gene expression and demonstrated that fluphenazine antagonized the 
effect of fluconazole on C. albicans clinical isolates.  All the participants in this study 
were on a single or combination of antipsychotic medications.  It is not known 
whether their drug particular drug regimes would have affected resistance to the most 
commonly used antifungal, fluconazole, in the yeast strains isolated from participants.  
The antipsychotic drug, fluphenazine was used in the present study because of its use 
in previous in vitro experiments (de Micheli et al., 2002; Coste et al., 2004; 
Manoharlal et al., 2011).  
 
Fluphenazine was one of the first medications classed as ‘antipsychotic drug’ and was 
approved by the FDA in 1959.  It is still widely used in the treatment of 
schizophrenia, particularly when it is the only antipsychotic medication available, in 
developing countries for example.  Although it is still available in Britain and North 
America, it is being replaced by newer generation of antipsychotic medications 
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(Matar et al., 2013).  The present study found that fluphenazine resulted in weak 
antifungal activity against C. albicans; it only affected the yeast growth at high 
concentrations (≥ 50µg/mL) (Figure 4.11).  However, when both medications were 
combined, fluphenazine was found to produce antagonistic effects towards 
fluconazole, both in disc diffusion assays (Figure 4.9) and the more quantitative 
checkerboard MIC assays (Figure 4.10 and Table 4.5). It remains to be determined 
whether the concentrations of medications achieved in the oral cavity would result in 
in vivo antagonism. It will also be important to determine whether other types of anti-
psychotic medications demonstrate antagonism of fluconazole antifungal activity.  
 
Although some of the participants were on flupentixol, a drug of a similar class to 
fluphenazine, none of the isolates from those participants showed any indication of 
having developed fluconazole resistance.  This is probably because the effect of 
fluphenazine is transient – causing up-regulation of the efflux pumps – and 
susceptibility to fluconazole may return to normal in the absence of fluphenazine.  It 
would have been interesting to know whether any of the participants had ever been 
treated with both fluconazole and fluphenazine, and if so whether the candidosis had 
responded to treatment.  The discovery that antagonism between fluphenazine and 
fluconazole occurs with C. albicans clinical isolates indicates that careful 
consideration may be necessary when prescribing fluconazole to patients currently 
taking fluphenazine or medications of a similar class.  Other antifungal agents such as 
nystatin lozenges (not readily available in New Zealand) or amphotericin B lozenges 


















The present study was focused on the oral health of participants who were taking 
antipsychotic medications.  This interest was due to the paucity of investigations of 
mucosal fungal infections in these individuals.  The goals for the present study were 
to determine the level of colonisation of Candida spp. in the oral cavity of individuals 
taking antipsychotic medications when compared to healthy controls and xerostomic 
patients who were not taking antipsychotic medication.  The Candida species that 
were present were identified and finally the antifungal susceptibility of the C. 
albicans detected was determined.  In this chapter, the topics that are going to be 
discussed are the characteristics of participants in this study, the effects of 
antipsychotic medications on the oral environment, Candida colonisation and oral 
candidosis in individuals taking antipsychotic medications and the azole resistance of 
C. albicans in those individuals.  This study has limitations that will also be discussed 







Gender differences in the prevalence of mental health illnesses vary across age groups 
(Afifi, 2007).  The majority of the participants in this study were males (78%).  This 
was consistent with the commonly accepted distribution of schizophrenia between 
sexes, where a systematic review has shown men to have a higher incidence of 
schizophrenia than women (male:female ratio of 1.4: 1) (McGrath and Susser, 2009).  
Schizophrenia is one of the most severe psychiatric disorders with an estimated 
prevalence of 0.7% to 1.0% of the worldwide population (Santos et al., 2012).  It is a 
mental disorder of thought, disorganised behaviour and can cause hallucinations, 
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delusions and illusions including cognitive impairment.  It belongs to the psychosis 
group of mental disorders, along with bipolar disorder and mania.  
5.2.2	General	Medical	Conditions	
 
Most of the participants in the present study suffered from schizophrenia (55.6%).  
The other medical conditions that presented along with their psychiatric problem were 
hypertension, depression, anxiety, eating disorders (bulimia and anorexia) and thyroid 
problems.  The presence of thyroid pathology is interesting since some studies 
reported antipsychotic medications and/or schizophrenia may cause imbalance in 
thyroid hormones levels (Santos et al., 2012).  Hypothyroidism may cause negative 
symptoms (depressive symptoms) in schizophrenia and hyperthyroidism may cause 
positive symptoms (psychosis) (Santos et al., 2012).  Long-term antipsychotic 
medications may elevate prolactin production via blocking dopamine receptors in the 
anterior pituitary thus inducing thyroid autoantibodies as well as reducing sex 
hormones causing sexual dysfunction and possibly accelerating osteoporosis in 




The majority of participants were on a combination of medications (6 of 9, 67%) 
including antipsychotic medications and prescriptions for their underlying medical 
illnesses.  According to a literature review study, there were 16 treatment 
recommendations in total available for the management of schizophrenia (Buchanan 
et al., 2010).  There were 11 revised treatment recommendations and 5 new treatment 
recommendations, grouped either by intervention or outcome.  The treatment 
recommendations were based on treatment for acute schizophrenia, maintenance 
therapy, treatment for residual symptoms, prophylactic antiparkinson treatment, 
treatment for acute agitation and medications for smoking cessation.  They found that 
the practice of polypharmacy in the treatment of schizophrenia was common since 
many patients will also have symptoms of depression (Buchanan et al., 2010).  
Further, many people had failed to respond adequately to previous single-item 
antipsychotic treatment.  Although there was no strong evidence of the efficacy of 
combination therapy, multiple medications were prescribed to address the issue of 
Chapter 5: Discussion 
	 105	
persistent psychopathological symptoms or other symptoms such as anxiety and 
cognitive impairment and also for the treatment of medical disorders for example 
antipsychotic-induced prolactin elevation or hormonal disturbances.  For example, the 
use of anticonvulsants for the treatment of treatment-resistant positive and negative 
symptoms, benzodiazepines for anxiety, antidepressants for depression and 
management of antipsychotic-related side effects such as tardive dyskinesia.  Sodium 
valproate is an anticonvulsant, frequently used as an adjunct in the treatment of 
psychiatric disorders as a mood stabiliser.  Other anticonvulsants that may be 
prescribed to patients are lamotrigine, clonazepam and carbamazepine (tegretol).  
Anticholinergic agents, such as benztropine or hypnotic agent such as zopiclone may 
also be added into the medications list to reduce the side effects of antipsychotic 
medications.  Other medications that were prescribed to participants in the current 





In the present study, three participants were tobacco smokers.  They were all males, 
with two of them diagnosed with schizophrenia.  In other studies it was found that the 
prevalence of cigarette smokers was higher in schizophrenia patients when compared 
to the overall population and people with other psychiatric disorders (de Leon, 1996; 
de Leon and Diaz, 2005).  The data in the current study did not show a high number 
of smokers probably due to limiting the category to smokers and non-smokers.  The 
data may show differences if quitters were identified in this study.  Smoking could be 
considered to be a form of self-medication for psychiatric patients since nicotine 
reduces the side effects of antipsychotic medications and helps eliminate cognitive 




The presence of dentures in the oral cavity may affect the oral Candida carriage. It 
has been shown that patients taking long-term antipsychotic medications had a higher 
prevalence of denture-related denture stomatitis and oral candidosis compared to 
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patients taking antidepressants (Lucas, 1993).  The low number of denture wearers 
found in this study is in accord with a previous study done investigating the 
community dwelling individuals living with psychiatric disorders, where it was found 
that they were less likely to use dentures because they did not have adequate 
determination to seek dental treatment due to their mental health state (McCreadie et 
al., 2004).  Not only do they not seek out denture construction for mental health and 
financial reasons but they also tend to get profound medication induced xerostomia.  
These resulted in poor denture retention, leading to ulcers, pain and ultimately them 
not being worn.  They often lost the dentures or had dentures made but did not use 
them due to problems with their dentures such as pain, gagging and difficulty in 




Dry mouth is a condition where salivary flow or output is decreased or reduced, with 
changes in the salivary composition, whilst xerostomia is the subjective feeling of dry 
mouth experienced by individuals (Hopcraft et al., 2010).  With changes in the 
salivary composition and output, multiple compounding effects usually follow.  These 
factors not only affect the individual’s general oral condition but also their quality of 
life.  The level of severity of dry mouth and xerostomia can be measured by using 
several investigation methods.  These methods can be classified into special imaging 
procedures to determine salivary gland activity, measurement of salivary output, 
observers’ assessments of the condition of the oral mucosa and dentition and 
instruments used to record patient-reported evaluation of xerostomia-related 




Scintigraphy is a special imaging procedure using Tc-pertechnetate.  This procedure 
captures information related to the movement of saliva from serum into the salivary 
glands (uptake), its concentration and then the movement and modification of saliva 
through ducts into the mouth (excretion). When combined with single-photon 
emission tomography, it can provide spatial information about the gland anatomical 
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volumes and their response to the variation of doses of the Tc-pertechnetate (Eisbruch 
et al., 2003).  However, due to the technical complexity and the need for nuclear 




Salivary output can be measured as an objective investigation for dry mouth.  The 
collection of unstimulated saliva, stimulated saliva after chewing, whole saliva 
collection and selective saliva collection from specific salivary glands are methods 
used for measuring salivary output.  Whole saliva measurement is considered 
acceptable for investigating the general level of xerostomia in patients or the 
relationship between symptoms and salivary output (Eisbruch et al., 2003).  The 
measurement of the production of unstimulated whole saliva is easy, but it is sensitive 
to the hydration status of the patients and medications that may induce xerostomia.  
This is one of the reasons why the method of unstimulated whole saliva collection 




Clinical examination of the oral cavity provides useful information on the patient’s 
oral environment.  The signs observed in a patient such as frothy saliva, dry shiny 
mucosa, depapillated or red, fissured tongue, lack of saliva pooling in the floor of the 
mouth, and the mouth mirror sticking to the buccal mucosa are signs of dry mouth.   
The present study identified the occurrence of dry mouth based on the presence of one 
or more sign of dry mouth (frothy saliva, dry shiny mucosa, depapillated or red, 
fissured tongue, lack of saliva pooling in the floor of the mouth, and the mouth mirror 
sticking to the buccal mucosa).  The clinical assessment was undertaken after the 
participants completed their XI questionnaires, which took approximately 5 to 10 
minutes, allowing sufficient time to assess whether the mouth was truly dry or moist.     
	




   
In the present study, the majority of participants (6 of 9 scored < 22 in the XI) 
reported less severe dry mouth symptoms.  Although at the lower end of the spectrum, 
the oral changes described in the present study were still sufficient for the individual 
to be aware of the condition and often resulted in a reduced quality of life and 
behaviour modification such as always carrying a water bottle, waking up at night to 




Participants who are taking multiple medications, especially those with an 
anticholinergic action may have a more severe dry mouth due to the synergistic 
effects of these medications with antipsychotic medications.  The participant with the 
highest XI score in the study (Table 3.6, Section 3.8.1) was on a combination of 
xerogenic medications, with clinical evidence of a dry mouth.   
 
Antipsychotic medications may cause multiple side effects on the oral environment 
including hyposalivation or conversely increased salivation in patients.  One of the 
two participants who had no evidence of dry mouth was taking quetiapine and 
flupentixol injection and the other one was taking risperidone only.  This finding 
contradicts the usual side effects of quetiapine and risperidone, since they both 
usually cause dry mouth (Bagnall et al., 2003; Srisurapanont et al., 2004).  One 
participant, on olanzapine alone, showed clinical signs of dry mouth, but did not have 
a high XI score suggesting this person experiences a less severe dry mouth.  The 
presence of dry mouth and the severity of xerostomia found in the present study was 
not exclusively due to the effect of antipsychotic medications, but due to the cocktail 
of medications, in particular those with xerostomic potential taken by the participants.    
 
Although clozapine may cause hypersalivation more often than dry mouth (Davydov 
and Botts, 2000), in the present study, participants taking clozapine were found to 
have clinical signs of dry mouth.  However, this might be due to other medications 
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with xerostomic potential taken along with their antipsychotic prescriptions such as 
lithium, haloperidol and citalopram.  
 
The present study did not investigate other side effects in the oral cavity that may 
appear in individuals taking antipsychotic medications.  Although the effects of 
antipsychotic medications on the oral environment did not appear significant, the dry 
mouth effect due to antipsychotic drug intake may reduce the quality of life for 
individuals.  Gerdin et al. (2005) studied the impact of dry mouth on the oral health-
related quality of life of elderly people.  They found dry mouth significantly affects 
the oral health-related quality of life of the elderly people.  In a different study, the 
combination of clinical symptoms, adverse effects of medications and the interactions 
between distress factors (psychological distress) and protective factors (coping, social 
support) affect the quality of life of hospitalised patients living with schizophrenia 
(Ritsner et al., 2002).  




There is little information currently available about the presence of oral candidal 
infection in patients taking antipsychotic medications.  Antipsychotic medications 
may not be the main cause for oral candidosis, although a study of patients on long-
term phenothiazine therapy participants were found to have a higher frequency of 
candidal infection and a higher mean number of Candida colony-forming units (CFU) 
than a control non-psychiatric group (Lucas, 1993).  While the natural host defence 
mechanisms against candidal infection are weakened by the xerostomia induced by 
antipsychotic medication, an in vitro study of phenothiazines, specifically 
chlorpromazine and trifluoperazine, showed an inhibition of C. albicans growth 
(Sharma et al., 2001) and growth of other Candida spp. including Candida tropicalis, 
Candida parapsilosis and Candida glabrata (Afeltra and Verweij, 2003) suggesting 
these medications have some antifungal activity.  
 
In the present study, four of nine participants were diagnosed with oral candidosis 
from smears.  They were on a combination of multiple antipsychotic medications 
along with other medications for underlying medical conditions.  One of the 
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participants with oral candidosis was on the combination of flupentixol (typical) and 
quetiapine (atypical).  Studies have documented dry mouth as the side effect of these 
medications (Eberhard and Helbom, 1986; Mullen et al., 2001).  Flupentixol is a very 
potent antipsychotic drug in the thioxantene category, introduced in 1965 for the 
treatment of various mental disorders (Jørgensen, 1980).  
  
In the present study, the level of oral Candida colonisation was quantified from the 
number of colony forming units (CFU) obtained from the saliva samples.  These 
findings were compared with healthy controls and participants with xerostomia not 
prescribed antipsychotic medications.  The numbers of CFU/mL in each of the 
participant group in this study were significantly higher than the number in the control 
group (H = 10.38, df = 2, p<0.05).  There was no statistical difference in CFU/mL 
between participants and xerostomia subjects (p>0.05), however there were 
statistically significant more CFU/mL in the participants compared with the healthy 
controls (p<0.05).  The species presumptively recognized from the colony colour on 
the CHROMagar™ Candida, that was present at the highest concentration was C. 
albicans.  Other species that were presumptively identified in the saliva samples were 






In the present study fluconazole resistance was measured using the Etest® method 
and the broth microdilution technique (liquid MIC susceptibility assay).  The Etest® 
plates were read according to the manufacturer’s instructions.  However, it was 
noticed that the yeast growth (from standardised 0.5 McFarland turbidity C. albicans 
inoculum lawns on the agar plates) was insufficient at 24 h to measure the MIC, thus 
the author took the readings at 48 h.  The presence of microcolonies within the entire, 
or almost the entire, elliptical zone of inhibition resulted in difficulties in determining 
the end-point when reading the Etest® values.  The difficulties observed in the 
present study were similar to those reported previously.  Similar patterns were 
observed more often with C. albicans and C. tropicalis compared to other Candida 
species (Colombo et al., 1995).  Five of the 12 isolates in the present study were 
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apparently resistant to fluconazole by the Etest® method.  Two pairs (W4a and W4b; 
W6a and W6b) showed a similar pattern of growth in the Etest® indicating that each 
pair might be isolates of the same strain of C. albicans.  The strains of C. albicans 
isolated in the present study were not identified prior to the susceptibility testing.  
Ideally, the strains should be identified using multi-locus sequence typing (MLST), 
which uses a DNA sequencing method to type strains.  The MIC values obtained from 
the broth microdilution technique were more consistent with previously reported 
susceptibilities of commensal isolates and more reliable with more reproducibility 
(Colombo et al., 1995).  In the present study, none of the clinical isolates (at 24 h) 
were found to be resistant to fluconazole as determined by liquid MIC; the breakpoint 
for resistance being 64 µg/mL (Pfaller et al., 2006; Pfaller et al., 2010a).  The CLSI 
guidelines allow readings to be obtained at 24 h or 48 h if there is insufficient growth.  
The MIC readings obtained from the Etest® for susceptible strains were in the lower 





The Etest® is a simple yet reliable tool available to quantify antifungal susceptibility 
in terms of MIC values.  The results obtained from the Etest® generally agree with 
the results obtained from the gold-standard broth microdilution technique (Colombo 
et al., 1995).  However, in the present study, five of 12 isolates (41.7%) gave MIC 
values of >256 µg/mL with the Etest® method, indicating resistance, compared to 
none with the liquid MIC susceptibility assay.  This is probably due to the difficulty 
in reading the Etest® MIC and the trailing growth of C. albicans in the liquid MIC.  
The Etest® is an instrument suitable for use for clinical isolates due to the simple and 
rapid process.  Well-trained and experienced clinical microbiology personnel are 
required to provide correct judgement and consistent MIC readings. 







Potential interactions between fluconazole and fluphenazine are not well documented 
and yet it is realistic to expect that this combination of medications might be 
prescribed together reasonably often.  The present study investigated the effect of this 
drug combination on C. albicans growth and viability using the disc diffusion method 
and the checkerboard liquid MIC synergism/antagonism assay.  Antagonistic 
interactions between fluphenazine and fluconazole were observed in the disc diffusion 
assay for all the isolates in this study.  However, in the checkerboard liquid MIC 
synergism/antagonism assay, antagonism was not seen for all isolates.  The 
checkerboard assay results were analysed using fractional inhibitory concentration 
index (FICI) calculations.  A FICI value of < 0.5 indicates a synergistic interaction, 
while an FICI value of > 4.0 indicates an antagonistic interaction (Odds, 2003).  A 
value between 0.5 and 4.0 indicates no significant interaction between the two 
medications.  Although using the FICI value has been a popular choice amongst 
bacteriologists and mycologists (Odds, 2003; Meletiadis et al., 2009), it can be 
inconsistent.  The FICI values differ with different cut-off MIC values pre-determined 
for each drug.  For example, if the MIC0 (total inhibition of yeasts) was used for all 
the medications, the end result of synergism/antagonism between all isolates differs 
from the MIC values taken at 80% of growth inhibition (MIC80).  The incubation 
period of the yeast growth also affects the results.  In the study done by Meletiadis 
and colleagues, the best incubation period for determining the MIC for antifungal 
combinations was found to be 24 h.  They proposed more research should be done in 
comparing the in-vivo and in-vitro results to correlate the FICI values with the 
pharmacodynamics in clinical situations.   
 
In the present study, for five out of 12 isolates antagonism between fluphenazine and 
fluconazole was observed.  Although the other isolates did not give a definite value of 
synergistic/antagonistic interactions, three of the isolates obtained a FICI value of 3.0 
indicating potential antagonism. In several cases antagonism was observed at the 
lowest fluphenazine concentration tested, 0.375 µg/mL. 




Individuals receiving fluphenazine via intramuscular injection (as a depot medication) 
are prescribed either 25 or 50 mg fluphenazine decanoate (FPZ-D) every two weeks, 
while oral fluphenazine hydrochloride (FPZ-H) is prescribed as 2.5 to 10 mg every 
six or eight hours.  Patients receiving 25 mg FPZ-D were found to have fluphenazine 
plasma concentrations of 0.17-0.61 ng/mL (Chang et al., 1985; Whelpton and Curry, 
1976), and the plasma concentration of fluphenazine in patients receiving 50 mg FPZ-
D ranges between 0.20 and 0.93 ng/mL (Chang et al., 1985).  An earlier study found 
the fluphenazine plasma level was between 1.02 and 3.48 ng/mL in the patients 
receiving 25 mg dose (Wiles and Gelder, 1979).  For patients receiving fluphenazine, 
the drug will enter saliva via the gingival crevicular fluid, but the concentration 
achieved in saliva has not been reported. It remains debatable as to whether 
antagonism between fluphenazine and fluconazole will be seen with oral C. albicans 
in vivo. Antagonism was seen in vitro at fluphenazine concentrations of 375 ng/mL. 
This was the lowest concentration tested. Further research is required to see if this 
effect is still seen at concentrations of fluphenazine and fluconazole achieved in saliva 
in vivo.  
 
The fluphenazine MIC values for the C. albicans isolates were all between 50 and 100 
µg/mL therefore the drug will not have an antifungal affect in vivo, as this 
concentration will not be achieved, but may reduce susceptibility of yeast to 






One of the limitations of the present study was the low number of recruited 
participants.  The study participants were limited to patients attending the Special 
Care Unit, Faculty of Dentistry, University of Otago.  This was one of the reasons for 
the low number of participants recruited into this study.  Individuals living with 
mental disorders or pscyhosis are not easy to deal with.  They sometimes have mood 
swings causing them to change their mind about previous decisions such as whether 
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to attend dental appointment.  Another factor contributing to the relatively low 
numbers of participants was the exclusion factor of certain other medical conditions 
being present along with their mental disorder.  Patients with medical conditions such 
as diabetes mellitus were not included in this study because the presence of diabetes 
may have acted as a confounding factor in the perception of oral dryness and Candida 
colonisation.  Patients with poor co-operation and impaired intellectual ability were 
excluded from this study.  Most of the patients attending the Special Care Unit needed 
a relative or support worker to accompany them to attend the clinic appointments.  
Some of the patients’ relatives or caregivers decided they were not suitable to be 
recruited into this study.  It was important to make sure the relatives or caregivers 
understood the purpose of this study and how it was performed to get their full 
support.  The data collection period was completed in a manner that was comfortable 
for the participants to avoid unnecessary stress on them.  They were provided with 




The method for determining dry mouth in the present study was limited to clinical 
assessment.  The volumes of unstimulated saliva collected in this study were not 
measured.  Results from the clinical assessment alone were insufficient to diagnose 
dry mouth.  The volumes of saliva collected in this study should have been measured 
to properly distinguish dry mouth and moist mouth.  The XI in the present study was 
used merely to determine the subjective feeling of xerostomia in participants taking 
antipsychotic medications.  Individuals with clinical signs of dry mouth do not 
necessarily experience a severe level of xerostomia.  This is probably due to the 
symptoms not being severe enough to be noticed by the individuals or perhaps they 
experienced a less severe form of xerostomia and thus they did not adopt xerostomia 




Most participants recruited into the present study were on polypharmacy.  Three 
participants were exclusively taking antipsychotic medications, while the other six 
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were on combinations of antipsychotic medications and medications for their 
underlying medical conditions.  Three participants were on a combination of typical 
and atypical antipsychotic medications; flupentixol and quetiapine; and haloperidol, 
clozapine and lithium.  The findings from the present study could not be directly 
correlated with the antipsychotic medications due to the intake of other medications 
with xerostomic potential that may contribute to the results.  For example, other 
medications such as antihypertensives may contribute to the presence of dry mouth in 
the participants.   




The present study exclusively tested C. albicans for fluconazole antifungal resistance 
and fluphenazine susceptibility.  The results were obtained from the broth 
microdilution technique and the synergism/antagonism discs diffusion assays.  
Fluconazole combined with the antipsychotic medication; fluphenazine was studied in 
the checkerboard synergism/antagonism susceptibility assay (broth microdilution 
technique).  The susceptibility of fresh C. albicans isolates towards other, more 
frequently used, antipsychotic medications belonging in the same group as 
fluphenazine was not determined due to time constraints and limited resources.  The 
present study was limited to studying fluconazole alone, without testing the other 




Findings from the present study indicated that azole antifungal resistance could be 
induced by fluphenazine in the C. albicans strains isolated from patients taking 
antipsychotic medication.  This is an important clinically relevant finding and 
deserving of further study.  I would recommend inclusion of more participants if 
similar studies were to be performed and a population-based study is recommended.  
Comparing findings from institutionalised individuals and uninstitutionalised 
individuals could also be performed in the future.  Institutionalised patients taking 
antipsychotic medications are presumably less well and taking a more complex range 
of medications that may have a more severe impact on the oral mucosa and lead to a 
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lower quality of life compared to patients living independently.  Recruiting 
participants exclusively taking typical antipsychotic medications or atypical 
antipsychotic medications should be considered to study the effect of antipsychotic 
medications on the oral environment without other confounding factors.  Other effects 
of the antipsychotic medications on the oral environment such as incidence of oral 
mucosal lesions could be another area of investigation.  The determination of dry 
mouth in the present study should have included measuring the salivary output either 
through whole unstimulated/stimulated saliva or collection from specific salivary 
glands.  Findings from the clinical evaluation of dry mouth alone were insufficient to 
accurately categorise the person as having a dry mouth.  Future studies on the impact 
of side effects of the antipsychotic medications on the oral health-related quality of 




The present study has found that there was a tendency towards antagonism between 
the combination of fluconazole and fluphenazine towards C. albicans.  This may 
induce fluconazole resistant oral candidal infections in individuals taking 
antipsychotic medications leading to treatment problems when treating these patients 
with fluconazole.  The risk of developing resistance to other types of azoles and 
antipsychotic medications requires investigation.  In the meantime treating oral 
candidosis with polyenes should be considered in patients taking antipsychotic 
medications in the same or similar class as the fluphenazines (phenothiazine derived 




























































































































































































































































































































































































































































































































































































































































Manager, Academic Committees, Mr Gary Witte
12/207
Professor A Rich
 Sir John Walsh Research Institute
Department of Oral Diagnostic and Surgical Sciences
Faculty of Dentistry
Dear Professor Rich,
I am again writing to you concerning your proposal entitled “Are patients on antipsychotic
drugs at risk of developing azole-resistant oral candidal infections”, Ethics Committee
reference number 12/207.
Thank you for your letter of 8th July 2014 addressing the issues raised by the Committee.
On the basis of this response, I am pleased to confirm that the proposal now has full ethical
approval to proceed.
Approval is for up to three years from the date of this letter. If this project has not been
completed within three years from the date of this letter, re-approval must be requested. If
the nature, consent, location, procedures or personnel of your approved application change,






































sheet	 carefully	before	deciding	whether	or	not	 to	participate.	 	 If	 you	decide	 to	









Zealand	population	experienced	mental	disorders	 at	 some	 time	 in	 their	 life.	 	A	
proportion	 of	 this	 group	will	 have	 been	 prescribed	 antipsychotic	medications.	
These	medications	have	several	adverse	effects	including	reducing	salivary	gland	
function	 leading	 to	 a	dry	mouth.	 	 People	with	dry	mouth	have	a	higher	 risk	of	
developing	fungal	infections.		This	study	aims	to	determine	the	number	and	the	
type	 of	 fungal	 infections	 in	 people	 taking	 antipsychotic	 medications.		








medications	 who	 come	 to	 the	 Special	 Care	 Unit,	 Faculty	 of	 Dentistry,	















	 	 	 	
What	will	Participants	be	Asked	to	Do?	
	
Should	the	potential	participants	agree	to	 take	part	 in	 this	project,	 they	will	be	
screened	 for	 dry	 mouth.	 	 They	 will	 be	 asked	 to	 complete	 a	 form	 with	 11	
questions	 marking	 their	 subjective	 symptoms	 of	 a	 dry	 mouth.	 	 	 All	 potential	
participants	will	have	a	standard	oral	mucosal	examination	to	check	for	clinical	




wooden	 spatula.	 	 If	 there	 is	 evidence	 of	 Candida	 infection	 elsewhere	 in	 the	
mouth,	 further	 smears	 will	 be	 taken.	 	 	 They	 will	 also	 be	 asked	 to	 rinse	 their	
mouth	with	10mL	bottled	water	which	will	be	collected	in	a	sterile	bottle.		There	











The	data	 collected	will	be	 securely	 stored	 in	 such	a	way	 that	only	 those	 in	 the	
































This	 study	 has	 been	 approved	 by	 the	 University	 of	 Otago,	 Human	 Ethics	
Committee.	 If	you	have	any	concerns	about	 the	ethical	conduct	of	 the	research	
you	 may	 contact	 the	 Committee	 through	 the	 Human	 Ethics	 Committee	
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My mouth feels dry
I have difficulty in eating dry food
I get up at night to drink
My mouth feels dry when eating a meal
I sip liquids to aid in swallowing food
I suck sweets or cough lollies to relieve 
dry mouth
I have difficulties in swallowing certain 
foods
The skin of my face feels dry
My eyes feel dry
My lips feel dry








Title: Fluconazole Resistance Against Oral Candida in Patients Taking 
Antipsychotic Medications 
Authors: W.S. MOHAMED THANI, E. MACFADYEN, A.M. RICH, and R.D. CANNON 
Department: Sir John Walsh Research Institute, University of Otago, Dunedin, New Zealand 
 
Objective: To determine the Candida species and colonisation level of the oral 
mucosa in people taking antipsychotic medications relative to healthy individuals and 
other xerostomic patients.  To investigate fluconazole resistance to other 
antispsychotics, as fluphenazine is known to cause resistance. 
Method: Consented participants aged between 20 and 70, who were currently on 
antipsychotic medications were enrolled.  Xerostomia symptoms were determined 
from the Xerostomia Inventory (XI) and clinical examinations.  Saliva rinses were 
collected. Smears were taken from the buccal mucosae and tongue, and other 
suspicious mucosa.  Smears were sent to Medlab for candida hyphae and yeast 
identification.  Saliva samples were titrated and plated onto Chromagar, then kept at 
37oC for 48 hours.  The colony-forming units (CFU) and species (from the colony 
colour) were recorded.  The susceptibility of the colonies towards fluconazole was 
measured using the E-test by making lawns of candida species with the optical density 
(OD) of 0.25 on the HDMI and MOPS agar.  Plates were incubated at 37oC for 48 
hours. 
 
Result: Current findings show that although 75% of participants have evidence of dry 
mouth clinically, they may not have symptoms (only a third scored high XIs).  More 
than 60% have positive oral candida hyphae and candida colonies.  Susceptibility 
testing is currently undertaken. 
 
Conclusion: Many antipsychotic medications were known to cause xerostomia and 
increased candida infections.  Investigating candidal infection and their resistance to 
fluconazole will address and potentially lead to more appropriate treatment.
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